[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1053
1. Carvalho A, Amaral Mendes R, Carvalho D, Carvalho JF: [Osteonecrosis of the mandible induced by intravenous bisphosphonates in oncological patients]. Acta Med Port; 2008 Sep-Oct;21(5):505-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Osteonecrose da mandíbula associada a bifosfonatos intravenosos em doentes oncológicos.
  • Case 2: Seventy years-old female patient undergoing treatment with bisphosphonates for adenocarcinoma of the breast was referred to an appointment of oral surgery due to bony exposure.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Breast Neoplasms / drug therapy. Female. Humans. Male. Multiple Myeloma / drug therapy

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187694.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


2. Sanderson MP, Abbott CA, Tada H, Seno M, Dempsey PJ, Dunbar AJ: Hydrogen peroxide and endothelin-1 are novel activators of betacellulin ectodomain shedding. J Cell Biochem; 2006 Oct 1;99(2):609-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that in breast adenocarcinoma MCF7 cells overexpressing pro-BTC, hydrogen peroxide (H2O2) was a powerful stimulator of ectodomain shedding.
  • [MeSH-minor] ADAM Proteins / genetics. ADAM Proteins / metabolism. Amyloid Precursor Protein Secretases. Animals. Betacellulin. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Calcimycin / pharmacology. Cell Line, Tumor. Cells, Cultured. Dipeptides / pharmacology. Female. Humans. Hydroxamic Acids / pharmacology. In Vitro Techniques. Intercellular Signaling Peptides and Proteins. Membrane Proteins / genetics. Membrane Proteins / metabolism. Metalloendopeptidases / antagonists & inhibitors. Mice. Muscle, Smooth, Vascular / drug effects. Muscle, Smooth, Vascular / metabolism. Protein Precursors / chemistry. Protein Precursors / metabolism. Protein Structure, Tertiary. Rabbits. Receptors, G-Protein-Coupled / agonists

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16676357.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK63363
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BTC protein, human; 0 / Betacellulin; 0 / Btc protein, mouse; 0 / Dipeptides; 0 / Endothelin-1; 0 / Hydroxamic Acids; 0 / Intercellular Signaling Peptides and Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide; 0 / Protein Precursors; 0 / Receptors, G-Protein-Coupled; 37H9VM9WZL / Calcimycin; BBX060AN9V / Hydrogen Peroxide; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.- / tumor necrosis factor-alpha convertase; EC 3.4.24.81 / ADAM10 protein, human
  •  go-up   go-down


3. Ivanović V, Dedović-Tanić N, Milovanović Z, Lukić S, Nikolić S, Baltić V, Stojiljković B, Budisin N, Savovski K, Demajo M, Dimitrijević B: Quantification of transforming growth factor beta 1 levels in metastatic axillary lymph node tissue extracts from breast cancer patients: a new specimen source. Anal Quant Cytol Histol; 2009 Oct;31(5):288-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of transforming growth factor beta 1 levels in metastatic axillary lymph node tissue extracts from breast cancer patients: a new specimen source.
  • OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGFbeta1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC.
  • Confirmatory, large-scale studies are needed to evaluate possible implications of this putative biomarker in BC diagnosis and treatment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701096.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1
  •  go-up   go-down


Advertisement
4. Beachkofsky TM, Wisco OJ, Osswald SS, Osswald MB, Hodson DS: Pulmonary cutaneous metastasis: a case report and review of common cutaneous metastases. Cutis; 2009 Dec;84(6):315-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of cutaneous metastatic disease carries a grave prognosis.
  • The most common cutaneous metastasizing carcinomas--breast, lung, and colorectal cancer--also are discussed.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20166573.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


5. Güth U, Wight E, Schötzau A, Langer I, Dieterich H, Rochlitz C, Herberich L, Holzgreve W, Mihatsch MJ, Singer G: Correlation and significance of histopathological and clinical features in breast cancer with skin involvement (T4b). Hum Pathol; 2006 Mar;37(3):264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation and significance of histopathological and clinical features in breast cancer with skin involvement (T4b).
  • A retrospective review was performed to investigate the prognostic significance and validity of the pathological and clinical TNM staging of noninflammatory skin involvement in breast cancer.
  • In the analysis of 80 patients with a tumor size from 2.1 to 5.0 cm, neither the appearance of classical clinical signs nor the histological diagnosis of infiltration of the epidermis was shown to be a relevant factor.
  • Our results challenge the validity of the TNM rules and recommendations concerning T4b breast cancer because it leads, in the majority of cases, to tumors of comparable extent and prognosis being placed in different categories.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613321.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


6. Rauf F, Kiyani N, Bhurgri Y: Metaplastic carcinoma of the breast, an intriguing rarity. Asian Pac J Cancer Prev; 2006 Oct-Dec;7(4):667-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic carcinoma of the breast, an intriguing rarity.
  • Metaplastic carcinoma breast is categorized as a rare heterogenous neoplasm generally characterized by a mixture of adenocarcinoma with dominant areas of spindle cell, squamous and/or other mesenchymal differentiation.
  • Twenty-four patients were identified with a mean age at diagnosis of 46.4 (+/-SD 3.8) years, and an age range of 28-68 years.
  • MCB is an uncommon breast malignancy and due to the lack of sufficiently large studies there is limited knowledge as to the pathogenesis, progress, best treatment protocols and prognosis.
  • [MeSH-major] Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17250450.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


7. Tanaka Y, Morimoto S, Maeda M, Naganuma T: Dysuria caused by pelvic metastasis from breast carcinoma was alleviated by multi-modality therapy with zoledronic acid. Breast J; 2010 Jan-Feb;16(1):98-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysuria caused by pelvic metastasis from breast carcinoma was alleviated by multi-modality therapy with zoledronic acid.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Pelvic Neoplasms / secondary. Pelvic Neoplasms / therapy. Urinary Retention / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Dysuria / diagnosis. Dysuria / etiology. Dysuria / therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Radiotherapy, Adjuvant. Recovery of Function. Time Factors. Treatment Outcome. Ultrasonography, Doppler. Urinary Catheterization / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968658.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; OYY3447OMC / pamidronate
  •  go-up   go-down


8. Gutmann EJ, Cates JM: Initial diagnosis of breast cancer via cytological examination of a pleural effusion: a rare event facilitated by recognition of an unusual morphological pattern. Diagn Cytopathol; 2005 Mar;32(3):177-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial diagnosis of breast cancer via cytological examination of a pleural effusion: a rare event facilitated by recognition of an unusual morphological pattern.
  • It is uncommon for breast carcinoma to present as a malignant serous effusion.
  • Here, we describe a case in which the initial diagnosis of an occult invasive ductal carcinoma of the breast was made via cytological examination of a pleural effusion.
  • Recognition of a cribriform architecture with intraluminal necrosis and microcalcifications in a cell block preparation was critical in making that diagnosis.
  • To our knowledge, this specific morphological pattern of breast carcinoma in a cell block preparation from an effusion has not been reported previously.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Biopsy, Needle. Diagnosis, Differential. Dyspnea / etiology. Female. Humans. Lung Neoplasms / diagnosis. Pleural Effusion, Malignant / pathology. Pulmonary Disease, Chronic Obstructive / complications

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690336.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Hatzung G, Grunwald S, Zygmunt M, Geaid AA, Behrndt PO, Isermann R, Kohlmann T, Ohlinger R: Sonoelastography in the diagnosis of malignant and benign breast lesions: initial clinical experiences. Ultraschall Med; 2010 Dec;31(6):596-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonoelastography in the diagnosis of malignant and benign breast lesions: initial clinical experiences.
  • PURPOSE: This prospective study aimed to compare sonoelastography, B-mode ultrasonography, and mammography in terms of their ability to distinguish benign from malignant breast lesions.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Elasticity Imaging Techniques / methods. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / ultrasonography. Adult. Aged. Biopsy / methods. Breast / pathology. Carcinoma, Ductal / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / ultrasonography. Female. Fibroadenoma / pathology. Fibroadenoma / ultrasonography. Humans. Middle Aged. Papilloma / pathology. Papilloma / ultrasonography. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20614414.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Yoshida S, Takahashi H: Expression of extracellular matrix molecules in brain metastasis. J Surg Oncol; 2009 Jul 1;100(1):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumors from 40 patients with brain metastasis (30 lung cancer, 10 breast cancer) were studied to investigate the expression-patterns of EGFR, MT1-MMP, MMP7, and CD44 using the immunostaining and RT -PCR analysis.
  • RESULTS: EGFR immunostaining was detected in 92% (23/25) and 70% (7/10) of brain metastasis from lung adenocarcinoma and breast cancer, respectively.
  • MT1-MMP immunostaining was also detected in 80% (20/25) and 50% (5/10) of brain metastasis from lung adenocarcinoma and breast cancer, respectively.
  • EGFR mRNA was detected in 83.3% (25/30) and 70% (7/10) of brain metastasis from lung cancer and breast cancer, respectively.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19402080.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


11. Giarnieri E, Alderisio M, Mancini R, Falasca C, Ricci A, Mariotta S, Giovagnoli MR: Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions. Oncol Rep; 2008 Feb;19(2):483-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions.
  • Serous effusions are frequently a clinical manifestation of metastatic disease, with lung, breast and ovarian carcinoma and mesothelioma leading the list.
  • The diagnosis of malignant effusion signifies disease progression and is associated with a worsening patient prognosis.
  • The purpose of this preliminary study is to investigate, by immunocytochemistry, TIMP-2 expression in non-neoplastic and metastatic adenocarcinoma pleural effusions.
  • We selected 16 cases of reactive mesothelio, 7 of normal mesothelio, 14 of lung adenocarcinoma, 9 from the ovary, 4 from the gastrointestinal tract and 3 from the breast.
  • In 23/30 cases (76%), we detected adenocarcinoma cells with strong TIMP-2 expression.
  • A statistical association was detected between TIMP-2 expression and metastatic adenocarcinoma cells compared to reactive and normal mesothelial cells (p<0.00003).
  • In conclusion, immunocytochemical detection of TIMP-2 could be considered an interesting marker in metastatic adenocarcinoma pleural effusions, and could possibly be used as a component of an antibody panel in diagnostic cytopathology.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Pleural Effusion, Malignant / diagnosis. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202798.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  •  go-up   go-down


12. Spector R, Liphshitz I, Barchana M, Kundel Y, Wasserberg N, Lelcuk S, Sulkes A, Brenner B: High incidence of non-upper aerodigestive primary tumors in patients with esophageal cancer. Dis Esophagus; 2008;21(8):718-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Earlier reports have described an association between esophageal cancer (EC) and high incidence of other primary tumors (OPTs) of the upper aerodigestive tract and breast cancer.
  • Two cohorts, Israeli National Cancer Registry registered colorectal cancer (CRC) patients and the general Israeli population, were used for reference; 297 EC patients (12.7%) had OPTs, including breast (18.9%), CRC (16.2%), prostate (8.8%), and bladder (8.4%) cancers.
  • Most OPTs were identified before (74.4%) or simultaneously with (13.8%) EC diagnosis.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564171.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ghetie C, Davies M, Cornfeld D, Suh N, Saif MW: Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer; 2008 Jul;7(4):283-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic disease is present in up to 20% of patients at the time of diagnosis of colorectal cancer.
  • A rare form of lung metastatic disease is endobronchial metastases, most commonly seen with breast cancer and colon cancer.
  • Pathology examination of the expectorated piece of tissue was consistent with colonic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Cough / etiology. Hemoptysis / etiology. Lung Neoplasms / secondary. Sputum

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cough.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650198.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


14. Tani Y, Suttie A, Flake GP, Nyska A, Maronpot RR: Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. Vet Pathol; 2005 May;42(3):306-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model.
  • The transgenic adenocarcinoma mouse prostate (TRAMP) model, designed for researching human prostatic cancer, was genetically engineered to harbor a transgene composed of the simian virus 40 Large-T/small-t antigen promoted by the rat probasin gene.
  • Some of the larger papillary, polypoid lesions exhibited a phyllodes pattern resembling that seen in mixed epithelial-stromal tumors of the breast, prostate, and seminal vesicles of humans.
  • Our recommended diagnosis of this lesion in the seminal vesicles is epithelial-stromal tumor.

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15872376.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Desmin; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


15. Yamada N, Nishida Y, Tsutsumida H, Hamada T, Goto M, Higashi M, Nomoto M, Yonezawa S: MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res; 2008 Apr 15;68(8):2708-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An understanding of the epigenetic changes of MUC1 may be of importance for diagnosis of carcinogenic risk and prediction of outcome for cancer patients.
  • [MeSH-minor] Adenocarcinoma. Base Sequence. Breast Neoplasms. Cell Line, Tumor. Colonic Neoplasms. DNA Primers. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Humans. Molecular Sequence Data. Pancreatic Neoplasms. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. L-Lysine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413738.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Histones; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger; 0 / RNA, Neoplasm; K3Z4F929H6 / Lysine
  •  go-up   go-down


16. Al-Kalaldeh JZ, Abu-Dahab R, Afifi FU: Volatile oil composition and antiproliferative activity of Laurus nobilis, Origanum syriacum, Origanum vulgare, and Salvia triloba against human breast adenocarcinoma cells. Nutr Res; 2010 Apr;30(4):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volatile oil composition and antiproliferative activity of Laurus nobilis, Origanum syriacum, Origanum vulgare, and Salvia triloba against human breast adenocarcinoma cells.
  • In the present study, selected spices used in Jordan were chemically analyzed and investigated for their antiproliferative activity to the adenocarcinoma of breast cell line (MCF7).
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiosperms / chemistry. Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Cell Proliferation / drug effects. Oils, Volatile / therapeutic use. Terpenes / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20534330.001).
  • [ISSN] 1879-0739
  • [Journal-full-title] Nutrition research (New York, N.Y.)
  • [ISO-abbreviation] Nutr Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Oils, Volatile; 0 / Plant Extracts; 0 / Rhodamines; 0 / Terpenes; 2609-88-3 / lissamine rhodamine B
  •  go-up   go-down


17. Dahl K, Westlin J, Kraaz W, Winqvist O, Bergkvist L, Thörn M: Identification of sentinel nodes in patients with colon cancer. Eur J Surg Oncol; 2005 May;31(4):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Lymphatic mapping and sentinel node biopsy entails better staging in malignant melanoma and breast cancer and we used this technique in patients with colon cancer to possibly improve detection of lymphatic spread.
  • Patients dying from metastatic disease had lymph-node metastases at diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Lymphatic Metastasis. Sentinel Lymph Node Biopsy / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837044.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Riall TS, Stager VM, Nealon WH, Townsend CM Jr, Kuo YF, Goodwin JS, Freeman JL: Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. J Am Coll Surg; 2007 May;204(5):803-13; discussion 813-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We determined the incidence of additional primary cancers that developed either before or after the diagnosis of invasive IPMN and compared it to the incidence of additional primary cancers in patients with sporadic pancreatic adenocarcinoma.
  • Ten point three percent had one or more extra-pancreatic primary cancers in addition to their pancreatic primary (10.3% in patients with sporadic adenocarcinoma and 10.1% in patients with invasive IPMNs, p = NS).
  • The most common sites of additional primary cancers were colorectal (20.1%), breast (19.9%), prostate (16.6%), urinary system (11.1%), and lung (9.8%).
  • In the 2,017 patients with additional primary cancer, 86% occurred before the diagnosis of pancreatic cancer and 14% occurred after the diagnosis of pancreatic cancer.
  • Although not as high as previously reported in smaller studies, the incidence is significant and comparable to the incidence seen in patients with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Carcinoma, Papillary / epidemiology. Neoplasms, Multiple Primary / epidemiology. Pancreatic Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481488.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Akbulut M, Zekioglu O, Kapkac M, Erhan Y, Ozdemir N: Fine needle aspiration cytology of glycogen-rich clear cell carcinoma of the breast: review of 37 cases with histologic correlation. Acta Cytol; 2008 Jan-Feb;52(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of glycogen-rich clear cell carcinoma of the breast: review of 37 cases with histologic correlation.
  • OBJECTIVE: To analyze fine-needle aspiration cytology (FNAC) material from 37 cases of breast glycogen-rich clear cell cancer (GRCC) and correlate cytomorphologic features with histologic appearance to determine characteristics of GRCC on FNAC.
  • STUDY DESIGN: We reviewed cytologic features of 37 cases of breast GRCC from the archives of Ege University Hospital diagnosed between 1994 and 2006.
  • The initial cytologic diagnoses were adenocarcinoma for 27 and atypical or suspicious for cancer for 10.
  • CONCLUSION: Breast GRCC is a rare, distinct category with cytologic features that overlap considerably with those of other carcinomas.
  • Awareness of variability in cytomorphologic appearance of GRCC and routine assessment for glycogen facilitate accurate diagnosis of these lesions by FNAC and enable prompt treatment of these poor-prognosis breast cancers.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Breast Neoplasms / diagnosis. Glycogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323277.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9005-79-2 / Glycogen
  •  go-up   go-down


20. Bagley CA, Bookland MJ, Pindrik JA, Ozmen T, Gokaslan ZL, Wolinsky JP, Witham TF: Fractionated, single-port radiotherapy delays paresis in a metastatic spinal tumor model in rats. J Neurosurg Spine; 2007 Sep;7(3):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 2- to 3-mm-diameter bur hole was drilled for the implantation of a section of CRL-1666 breast adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Animals. Breast Neoplasms / pathology. Cell Line, Tumor. Disease Models, Animal. Dose Fractionation. Female. Neoplasm Transplantation. Rats. Rats, Inbred F344. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877267.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fulciniti F, Losito S, Botti G, Di Mattia D, La Mura A, Pisano C, Pignata S: Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years. Ann Oncol; 2008 Apr;19(4):682-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years.
  • Besides primary neoplasms, the breast can host a number of metastases: these rarely do have a typical presentation, so FNC is requested for their cytomorphological assessment.
  • PATIENTS AND METHODS: This report describes nine consecutive cases in which a cytopathological diagnosis of metastasis to the breast was carried out on FNC samples.
  • CONCLUSION: The cytopathological diagnosis of metastatic neoplasms to the breast is not always straightforward, especially in the absence of a clinical history of cancer.
  • The usage of improved cytopathological criteria combined with immunocytochemistry may be of great diagnostic help in the identification of breast metastases.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048381.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Gao P, Bauvy C, Souquère S, Tonelli G, Liu L, Zhu Y, Qiao Z, Bakula D, Proikas-Cezanne T, Pierron G, Codogno P, Chen Q, Mehrpour M: The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem; 2010 Aug 13;285(33):25570-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we provide evidence that gossypol induces autophagy followed by apoptotic cell death in both the MCF-7 human breast adenocarcinoma and HeLa cell lines.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Gossypol .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tohoku J Exp Med. 1999 Sep;189(1):51-7 [10622208.001]
  • [Cites] FEBS Lett. 2008 Oct 15;582(23-24):3367-73 [18775705.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jul;2(7):545-50 [11433369.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Dev Cell. 2003 Oct;5(4):539-45 [14536056.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15077-82 [14657337.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1809-20 [14638851.001]
  • [Cites] Dev Cell. 2004 Apr;6(4):463-77 [15068787.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1500-2 [15131264.001]
  • [Cites] Cell Death Differ. 2004 Sep;11(9):1046-8 [15143348.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8):2052-8 [2539251.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] J Cell Physiol. 2009 Jan;218(1):13-21 [18767026.001]
  • [Cites] Biochem Pharmacol. 2008 Dec 1;76(11):1563-76 [18762177.001]
  • [Cites] Methods Enzymol. 2009;452:47-61 [19200875.001]
  • [Cites] Autophagy. 2009 May;5(4):558-60 [19337026.001]
  • [Cites] Cell Death Differ. 2009 Jul;16(7):966-75 [19325568.001]
  • [Cites] Cell Death Differ. 2009 Jul;16(7):1030-9 [19390557.001]
  • [Cites] Nature. 2009 Oct 1;461(7264):654-8 [19794493.001]
  • [Cites] Am J Physiol Cell Physiol. 2010 Apr;298(4):C776-85 [20089931.001]
  • [Cites] Curr Opin Cell Biol. 2010 Apr;22(2):140-9 [20097051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 May 18;107(20):9424-9 [20439739.001]
  • [Cites] Cell Death Differ. 2010 Dec;17(12):1867-81 [20508647.001]
  • [Cites] Science. 2004 Nov 5;306(5698):990-5 [15528435.001]
  • [Cites] Nat Cell Biol. 2004 Dec;6(12):1221-8 [15558033.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9314-25 [15602573.001]
  • [Cites] Cell. 2005 Jan 28;120(2):237-48 [15680329.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):726-34 [16148885.001]
  • [Cites] Cell. 2005 Sep 23;122(6):927-39 [16179260.001]
  • [Cites] Cell Death Differ. 2005 Nov;12 Suppl 2:1509-18 [16247498.001]
  • [Cites] Cell Death Differ. 2005 Nov;12 Suppl 2:1542-52 [16247502.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):886-97 [16239905.001]
  • [Cites] J Soc Biol. 2005;199(3):233-41 [16471263.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2885-8 [16540632.001]
  • [Cites] FASEB J. 2006 Oct;20(12):2147-9 [16935937.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):75-86 [17200184.001]
  • [Cites] Life Sci. 2007 Jan 30;80(8):767-74 [17156797.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2007 Mar;34(3):230-7 [17250644.001]
  • [Cites] EMBO J. 2007 May 16;26(10):2527-39 [17446862.001]
  • [Cites] Cell Death Differ. 2007 Jul;14(7):1247-50 [17431417.001]
  • [Cites] FEBS Lett. 2007 Jul 24;581(18):3396-404 [17618624.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Sep;8(9):741-52 [17717517.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Nov;8(11):931-7 [17712358.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2861-73 [18006683.001]
  • [Cites] Nat Rev Cancer. 2007 Dec;7(12):961-7 [17972889.001]
  • [Cites] Biochimie. 2008 Feb;90(2):313-23 [17928127.001]
  • [Cites] Cancer Lett. 2008 Jun 18;264(2):192-200 [18314260.001]
  • [Cites] Autophagy. 2008 Jul;4(5):574-80 [18362515.001]
  • [Cites] Mol Cell. 2008 Jun 20;30(6):678-88 [18570871.001]
  • [Cites] Cell Death Differ. 2008 Aug;15(8):1318-29 [18421301.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1971-80 [18566329.001]
  • [Cites] Autophagy. 2008 Nov;4(8):1083-5 [18849663.001]
  • [Cites] EMBO Rep. 2001 Apr;2(4):330-5 [11306555.001]
  • (PMID = 20529838.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATG5 protein, human; 0 / Androstadienes; 0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Contraceptive Agents, Male; 0 / Membrane Proteins; 0 / Microtubule-Associated Proteins; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; KAV15B369O / Gossypol; XVA4O219QW / wortmannin
  • [Other-IDs] NLM/ PMC2919121
  •  go-up   go-down


23. Yasuda M, Akiyama N, Miyamoto S, Warabi M, Takahama Y, Kitamura M, Yakushiji F, Kinoshita H: Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma. Pituitary; 2010;13(1):39-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though we conducted systemic investigations including chest and abdomen enhanced computer tomography, transbronchial lung biopsy, and bone marrow biopsy, the diagnosis was not confirmed.
  • Inadvertently, a breast cancer was found, and the surgical specimen proved that the patient had double cancer-adenocarcinoma and IVLBCL.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica / pathology. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cranial Nerves / physiology. Cranial Nerves / physiopathology. Female. Humans. Neoplasms, Second Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Acta Neuropathol. 1999 Mar;97(3):311-6 [10090680.001]
  • [Cites] Endocr J. 2005 Oct;52(5):543-9 [16284431.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):112-23 [2420221.001]
  • [Cites] Am J Med. 1999 Aug;107(2):169-76 [10460050.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3168-73 [17577023.001]
  • [Cites] Acta Neurochir (Wien). 2008 Aug;150(8):833-6 [18574548.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1470-6 [11297569.001]
  • [Cites] Pituitary. 2011 Jun;14 (2):194-7 [19123039.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1525-7 [18053461.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):81-117, vi [10207686.001]
  • [Cites] Australas Radiol. 2000 Feb;44(1):112-4 [10761271.001]
  • [Cites] Am J Clin Pathol. 1979 Jun;71(6):724-7 [377944.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):46-9 [19229666.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] Pituitary. 2009;12(1):76-9 [18205050.001]
  • [Cites] Am J Med. 1996 Nov;101(5):563-4 [8948282.001]
  • [Cites] Endocr Pract. 2003 Jul-Aug;9(4):296-300 [14561574.001]
  • [Cites] Wien Klin Wochenschr. 2006 Jul;118(13-14):422-5 [16865648.001]
  • [Cites] Am J Med Sci. 2004 Aug;328(2):124-8 [15311173.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):231-2 [10706771.001]
  • [Cites] Histopathology. 1997 Aug;31(2):161-6 [9279568.001]
  • [Cites] Pituitary. 2000 May;2(4):283-7 [11081150.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):335-341 [12114795.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):236-44 [18081700.001]
  • [Cites] J R Soc Med. 1997 May;90(5):274-5 [9204025.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 May;23(5):838-40 [12006288.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):236-9 [15224358.001]
  • [Cites] Folia Neuropathol. 2007;45(3):144-8 [17849366.001]
  • [Cites] Rinsho Shinkeigaku. 1999 Nov;39(11):1160-3 [10689943.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2000 Jan;38(1):34-8 [10723949.001]
  • [Cites] No To Shinkei. 1998 Dec;50(12):1133-41 [9989361.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):88-91 [8225384.001]
  • [Cites] N Engl J Med. 1994 Sep 29;331(13):861-8 [8078533.001]
  • [Cites] Dermatology. 2004;209(2):135-7 [15316168.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):130-3 [11216706.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):246-50 [12480233.001]
  • [Cites] No Shinkei Geka. 1998 Jan;26(1):53-8 [9488992.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1611-6 [15370213.001]
  • [Cites] Medicine (Baltimore). 1999 Jul;78(4):236-69 [10424206.001]
  • [Cites] Med Pediatr Oncol. 2001 Mar;36(3):392-5 [11241445.001]
  • [Cites] Cas Lek Cesk. 2008;147(11):569-73 [19097361.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1738-45 [8156502.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):227-31 [15072472.001]
  • [Cites] Blood. 2007 Jan 15;109(2):478-85 [16985183.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3189-95 [18506023.001]
  • [Cites] Endocrine. 2008 Aug-Dec;34(1-3):11-6 [18937075.001]
  • [Cites] J Clin Neurosci. 2008 Oct;15(10):1148-51 [18653342.001]
  • (PMID = 19707877.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


24. Ghodrati Azadi H, Ghaffari SM, Riazi GH, Ahmadian S, Vahedi F: Antiproliferative activity of chloroformic extract of Persian Shallot, Allium hirtifolium, on tumor cell lines. Cytotechnology; 2008 Mar;56(3):179-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the in vitro effects of chloroformic extract of A. hirtifolium and its Allicin on the proliferation of HeLa (cervical cancer), MCF7 (human, caucasion, breast, adenocarcinoma) and L929 (mouse, C3H/An, connective) cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chin Med J (Engl). 2007 Aug 5;120(15):1336-42 [17711740.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2000 Feb;46(1):199-214 [10726985.001]
  • [Cites] Planta Med. 1992 Aug;58(4):345-50 [17226483.001]
  • [Cites] Planta Med. 1991 Jun;57(3):263-70 [17226157.001]
  • [Cites] Phytomedicine. 2006 Nov;13(9-10):624-9 [17085291.001]
  • [Cites] Biofactors. 2006;26(2):93-103 [16823096.001]
  • [Cites] Nutr Cancer. 2006;54(1):111-42 [16800779.001]
  • [Cites] Neoplasma. 2006;53(3):191-9 [16652187.001]
  • [Cites] Am Fam Physician. 2005 Jul 1;72(1):103-6 [16035690.001]
  • [Cites] Arch Pharm Res. 2005 Apr;28(4):391-4 [15918510.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):325-31 [15713903.001]
  • [Cites] Anal Biochem. 1998 Dec 15;265(2):317-25 [9882409.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 2;1379(2):233-44 [9528659.001]
  • [Cites] Atherosclerosis. 1998 Aug;139(2):333-9 [9712340.001]
  • [Cites] Nucleic Acids Res. 1994 Dec 11;22(24):5506-7 [7816645.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Mycologia. 1977 Mar-Apr;69(2):341-8 [865503.001]
  • [Cites] Antimicrob Agents Chemother. 1977 Apr;11(4):743-9 [856026.001]
  • [Cites] Eur J Pharmacol. 2004 Feb 6;485(1-3):97-103 [14757128.001]
  • [Cites] Mol Cancer Ther. 2003 Dec;2(12):1295-301 [14707270.001]
  • [Cites] Anal Bioanal Chem. 2003 Oct;377(4):749-56 [12923610.001]
  • [Cites] Anal Biochem. 2002 Aug 1;307(1):76-83 [12137782.001]
  • [Cites] J Oral Pathol Med. 2002 Mar;31(3):142-6 [11903819.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3519-23 [11848518.001]
  • [Cites] Nutr Cancer. 2000;38(2):245-54 [11525603.001]
  • [Cites] J Nutr. 2001 Mar;131(3s):1010S-5S [11238807.001]
  • [Cites] Microbes Infect. 1999 Feb;1(2):125-9 [10594976.001]
  • [Cites] Lipids Health Dis. 2007;6:5 [17328819.001]
  • (PMID = 19002856.001).
  • [ISSN] 0920-9069
  • [Journal-full-title] Cytotechnology
  • [ISO-abbreviation] Cytotechnology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2553628
  •  go-up   go-down


25. Lovett DH, Cheng S, Cape L, Pollock AS, Mertens PR: YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun; 2010 Jul 30;398(3):482-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis.
  • YB-1 is linked to poor prognosis in breast carcinoma and is a strong predictor of relapse and disease-specific survival.
  • Non-invasive MCF-7 breast adenocarcinoma cells were transfected with YB-1/EGFP.
  • We conclude that YB-1 contributes to the development of an invasive, metastatic breast carcinoma phenotype by enhanced presentation of MT1-MMP at the sites of cellular invasion.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] EMBO J. 2001 Oct 1;20(19):5491-502 [11574481.001]
  • [Cites] RNA Biol. 2009 Jan-Mar;6(1):59-64 [19098458.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18241-8 [12604611.001]
  • [Cites] Bioessays. 2003 Jul;25(7):691-8 [12815724.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] J Cell Sci. 2003 Oct 1;116(Pt 19):3905-16 [12915589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(19):7322-6 [3174636.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15074-83 [8663054.001]
  • [Cites] Nat Med. 1997 Apr;3(4):447-50 [9095180.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22905-12 [9278454.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):32957-65 [9830047.001]
  • [Cites] J Cell Sci. 1999 Oct;112 ( Pt 20):3487-96 [10504297.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7702-11 [15615704.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4078-87 [15899797.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30564-73 [15985431.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4872-9 [16651443.001]
  • [Cites] EMBO J. 2007 Mar 21;26(6):1499-510 [17332756.001]
  • [Cites] BMC Biochem. 2008;9:23 [18793384.001]
  • [Cites] Breast Cancer Res. 2008;10(5):R86 [18925950.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • (PMID = 20599698.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R56 DK039776; United States / NIDDK NIH HHS / DK / DK039776-21; United States / NIDDK NIH HHS / DK / DK059383-05; United States / NIDDK NIH HHS / DK / R01 DK039776-21; United States / NIDDK NIH HHS / DK / K08 DK059383-05; United States / NIDDK NIH HHS / DK / R01 DK039776; United States / NIDDK NIH HHS / DK / R01-DK39776; United States / NIDDK NIH HHS / DK / KO8-DK59381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Y-Box-Binding Protein 1; 0 / YBX1 protein, human; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS225358; NLM/ PMC2925540
  •  go-up   go-down


26. Breiting LB, Christensen L, Dahlstrøm K, Winther JF, Breiting VB, Kalialis LV: [Primary mucinous carcinoma of the skin--a literature review]. Ugeskr Laeger; 2008 Oct 20;170(43):3399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is often misdiagnosed as it has an uncharacteristic gross appearance - and may microscopically resemble a cutaneous metastasis from a mucinous carcinoma of the breast, gastrointestinal tract, lungs, ovaries or prostate.
  • [MeSH-major] Adenocarcinoma, Mucinous. Skin Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Recurrence, Local. Prognosis. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / pathology. Sweat Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976593.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 40
  •  go-up   go-down


27. Chroneou A, Katsaounou P, Gangadi M, Pampukos S, Kougianos K, Zias N, Politis G: An unusual cause of dyspnea in a patient with relapsing breast cancer. Lung; 2006 Jul-Aug;184(4):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of dyspnea in a patient with relapsing breast cancer.
  • A 57-year-old woman with breast cancer had progressive dyspnea that worsened when in the supine position.
  • Determination of (VC) when standing and in the supine position and measurement of trandiaphragmatic pressure should reveal this uncommon diagnosis.
  • [MeSH-major] Adenocarcinoma / complications. Breast Neoplasms / complications. Dyspnea / etiology. Neoplasm Recurrence, Local / complications. Respiratory Paralysis / etiology


28. Da Ines D, Chabrot P, Cassagnes L, Merle P, Filaire M, Ravel A, Garcier JM, Boyer L: [Endovascular treatment of SVC syndrome from neoplastic origin: a review of 34 cases]. J Radiol; 2008 Jul-Aug;89(7-8 Pt 1):881-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Traitement endovasculaire du syndrome cave supérieur d'origine néoplasique: à propos de 34 patients.
  • MATERIALS AND METHODS: Thirty-four patients were treated between January 2000 and February 2007: 21 males and 13 females, aged 44-81 years, with non-small-cell lung carcinoma in 27 cases (79%), small-cell lung carcinoma in 5 cases (15%) and metastatic breast adenocarcinoma to the mediastinum in 2 cases (6%).

  • MedlinePlus Health Information. consumer health - Angioplasty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772750.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Xu WG, Dai D, Fang N, Song XY, Wang J, Zhu YJ, Men XY: [Molecular imaging for PET-CT reporter gene in breast adenocarcinoma (HSV1-tk) of subcutaneous xenografts in living nude mice]. Zhonghua Yi Xue Za Zhi; 2009 Dec 29;89(48):3420-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular imaging for PET-CT reporter gene in breast adenocarcinoma (HSV1-tk) of subcutaneous xenografts in living nude mice].
  • OBJECTIVE: To study the in vitro accumulation of (18)F-FHBG, its in vivo distribution and (18)F-FHBG PET-CT imaging for reporter gene (HSV1-tk) in nude mice with a xenograft of breast adenocarcinoma.
  • METHODS: The in vitro uptake of (18)F-FHBG in tumor cells of T47D and T47D-tk and the distribution of (18)F-FHBG in normal Kunming mice and nude mice with breast adenocarcinoma xenograft were detected by well-type gamma counter.
  • Reporter gene PET-CT imaging with (18)F-FHBG was performed in nude mice with a xenograft of breast adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Breast Neoplasms / radionuclide imaging. Genes, Reporter. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223118.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 9-(4-fluoro-3-hydroxymethylbutyl)guanine; 0 / Fluorine Radioisotopes; 5Z93L87A1R / Guanine
  •  go-up   go-down


30. Barbosa LA, Teixeira CR: Erythema multiforme associated with prophylactic use of phenytoin during cranial radiation therapy. Am J Health Syst Pharm; 2008 Jun 1;65(11):1048-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: A 60-year-old woman with intraductal adenocarcinoma of the breast and cerebral metastasis who had an implanted central venous catheter arrived at the hospital for the treatment of cerebral metastasis.
  • CONCLUSION: A patient with intraductal adenocarcinoma of the breast and cerebral metastasis developed erythema multiforme after receiving concurrent phenytoin and radiation therapy.
  • [MeSH-minor] Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Female. Humans. Middle Aged. Seizures / etiology. Seizures / prevention & control. Stevens-Johnson Syndrome / diagnosis. Stevens-Johnson Syndrome / etiology

  • Genetic Alliance. consumer health - Erythema Multiforme.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. PHENYTOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499877.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 6158TKW0C5 / Phenytoin
  •  go-up   go-down


31. Tozaki M, Fukuda K, Suzuki M: Dynamic high-spatial-resolution MR imaging of invasive ductal carcinoma: influence of histological scirrhous component on MR descriptors. Magn Reson Med Sci; 2006 Oct;5(3):137-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Ductal, Breast / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Invasiveness / diagnosis. Retrospective Studies

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139139.001).
  • [ISSN] 1347-3182
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA: In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol; 2005 Aug;56(2):115-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • "Head to head" comparison with 17-allylamino-17-demethoxygeldanamycin (17-AAG, NSC 330507) revealed 17-DMAG to possess potent activity against certain cell types, e.g., MDA-MB-231 breast carcinoma and HL60-TB leukemia which were relatively insensitive to 17-AAG.
  • 17-DMAG in an aqueous vehicle at 7.5-15 mg/kg per day for 3 days on days 1-3, 8-10 and 13-17, or 1-5 and 8-12 showed evidence of antitumor activity by the parenteral and oral routes in the MEXF 276 and MEXF 989 melanomas and by the parenteral route in the LXFA 629 and LXFS 650 adenocarcinoma and small-cell carcinoma models.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791458.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-270; United States / NCI NIH HHS / CM / N01-CM-97017; United States / NCI NIH HHS / CO / N01-CO 12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Lactams, Macrocyclic; 0 / Quinones; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  •  go-up   go-down


33. Wang F, Wang Z, Wu J, Qu W, Yao W, Zhao J, Liu Z: The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR. Nucl Med Biol; 2008 Aug;35(6):665-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
  • PURPOSE: To evaluate the value of (99m)Tc-octreotide acetate (hereafter, (99m)Tc-octreotide) somatostatin receptor (SSTR) scintigraphy in the detection of primary breast cancer and to correlate with expression of SSTRs.
  • MATERIALS AND METHODS: Fifty-four female and 1 male patients (range, 17-77 years; mean age, 48 years) with palpable breast lesion were included in this study. (99m)Tc-octreotide and (99m)Tc-MIBI scintigraphy were undertaken in all patients, and the region of interest was drawn around each lesion.
  • Final clinical diagnosis was confirmed by histopathological analysis.
  • RESULTS: Thirty-five patients were confirmed to have infiltrative ductal breast carcinoma, 1 patient with cellular cancer, 1 patient with adenocarcinoma and 18 patients had benign lesions.
  • CONCLUSION: (99m)Tc-octreotide acetate scintigraphy was sensitive for the detection of primary lesion of breast cancer; however, nonspecific breast tissue uptake hampered the specificity and clinical value in the detection of lymph node metastasis.
  • Five subtypes of SSTR mRNA and protein SSTR2 and SSTR5 were expressed variably in breast cancer due to tumor heterogeneity. (99m)Tc-octreotide imaging may hold promise in the evaluation of the level of SSTR2 in vivo.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds / pharmacokinetics. Receptors, Somatostatin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18678351.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


34. Kitajima A, Amano S, Sakurai K, Enomoto K, Matsuo S, Negishi N, Oinuma T, Nemoto N: [A case of breast cancer detected by MRI mammography after Hollywood syndrome]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1786-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of breast cancer detected by MRI mammography after Hollywood syndrome].
  • A-64-year-old woman, who had been treated with augmentation mammaplasty 40 years ago, came to our hospital complaining of left breast pain.
  • The mass was ill-defined, located in the upper outer quadrant area of her breast, and was 2 cm in diameter.
  • The diagnosis was Class IV by the fine needle aspiration biopsy cytology.
  • We diagnosed the left breast cancer being in T2N0M0, Stage IIA, then we carried out Bt (Auchincloss method) and Sentinel lymph node biopsy (SLNB).
  • The histological diagnosis was papillotubular carcinoma, f+, n+ (8/11).
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Implants. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Magnetic Resonance Imaging


35. Smymiotis V, Theodosopoulos T, Marinis A, Goula K, Psychogios J, Kondi-Pafiti A: Metastatic disease in the breast from nonmammary neoplasms. Eur J Gynaecol Oncol; 2005;26(5):547-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic disease in the breast from nonmammary neoplasms.
  • Breast cancer is the leading cause of death from cancer in women.
  • The metastatic involvement of the breast from nonmammary neoplasms is a relatively rare condition.
  • We present seven patients with metastasis in the breast from extramammary tumors.
  • The primary malignancies were equally distributed between non-hematological (1 renal adenocarcinoma, 1 melanoma, 1 leiomyosarcoma) and hematological (1 non-Hodgkin's, 2 Hodgkin's lymphomas and 1 leukemia).
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adolescent. Adult. Aged. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / secondary. Diagnosis, Differential. Female. Hodgkin Disease / diagnosis. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / secondary. Leiomyosarcoma / diagnosis. Leiomyosarcoma / secondary. Leukemia / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Male. Melanoma / diagnosis. Melanoma / secondary. Neoplasm Metastasis. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Uterine Neoplasms / diagnosis. Uterine Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285577.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


36. Cavanna L, Lazzaro A, Vallisa D, Civardi G, Artioli F: Role of image-guided fine-needle aspiration biopsy in the management of patients with splenic metastasis. World J Surg Oncol; 2007;5:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytohistological diagnosis, when done, is made prevalently by splenectomy.
  • Reports on splenic percutaneous biopsies in the diagnosis of splenic metastasis are fragmentary and very poor.
  • Among these 160 patients, 12 cases with the final diagnosis of solitary splenic metastases were encountered and they form the basis of this report.
  • Eight patients had a known primary cancer at the time of the diagnosis of splenic metastasis: 3 had breast adenocarcinoma, 2 colon adenocarcinoma, 2 melanoma and 1 lung adenocarcinoma.
  • Four patients were undiagnosed at the time of the appearance of splenic metastasis and subsequent investigations showed adenocarcinoma of the lung in 2 patients and colon adenocarcinoma in the remaining 2.
  • The splenic biopsies allowed a cytological diagnosis of splenic metastasis in all the 12 patients and changed clinical management in all cases.
  • CONCLUSION: These results indicate that UG-FNAB is a successful technique for diagnosis of splenic metastasis allowing an adequate treatment of the affected patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1995 May-Jun;80(3):241-3 [7672717.001]
  • [Cites] J Clin Ultrasound. 1994 Mar-Apr;22(3):161-6 [8169235.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):933-7 [10587123.001]
  • [Cites] Am J Hematol. 2001 Jun;67(2):93-9 [11343380.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2932-6 [1591686.001]
  • [Cites] Ugeskr Laeger. 1992 Mar 2;154(10):644 [1542972.001]
  • [Cites] Acta Cytol. 1991 Sep-Oct;35(5):560-2 [1927200.001]
  • [Cites] Radiology. 1990 Jan;174(1):43-7 [2403684.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):72-7 [2293872.001]
  • [Cites] Acta Cytol. 1988 Jul-Aug;32(4):552-4 [2456657.001]
  • [Cites] Radiology. 1986 Nov;161(2):289-91 [3763890.001]
  • [Cites] Eur J Cancer Clin Oncol. 1986 Feb;22(2):225-7 [3516708.001]
  • [Cites] World J Surg. 1985 Jun;9(3):468-76 [4040300.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):59-65 [6600326.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1116-8 [14674093.001]
  • [Cites] Am J Clin Oncol. 2001 Jun;24(3):311-2 [11404507.001]
  • [Cites] Am J Clin Oncol. 2001 Jun;24(3):306-10 [11404506.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):312-6 [9143823.001]
  • [Cites] Acta Cytol. 1993 Mar-Apr;37(2):158-62 [8465634.001]
  • (PMID = 17274814.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1800304
  • [General-notes] NLM/ Original DateCompleted: 20070808
  •  go-up   go-down


37. Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, André J, Bobin JY: Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clin Breast Cancer; 2008 Apr;8(2):168-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
  • PURPOSE: The aim of the present investigation was to evaluate the prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) tissue contents in primary breast adenocarcinoma.
  • PAI-1 is an independent prognostic factor in particular in pN0 breast ductal carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Plasminogen Activator Inhibitor 1 / metabolism. Urokinase-Type Plasminogen Activator / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621614.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Plasminogen Activator Inhibitor 1; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


38. Kropczyński G, Gabriel A, Kusz D, Ryś J, Miszczyk L, Paściak M: Influence of the type of neoplasm and treatment on the survival of patients with malignant spinal tumours. Ortop Traumatol Rehabil; 2009 Jan-Feb;11(1):27-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The most common types of neoplasms producing spinal metastases (in patients who underwent surgery) were: breast cancer, prostatic adenocarcinoma and kidney cancer.
  • Multiple myeloma was the most frequent diagnosis among primary bone neoplasms.
  • The survival of patients with multiple myeloma was statistically longer than the survival of patients with renal, breast and prostatic cancer metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240681.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


39. Mariappan MR, Lagera JE, Fadare O, Sibley RK: A 69-year-old woman with a vulvar lesion. Phyllodes tumor of the vulva. Arch Pathol Lab Med; 2006 Jan;130(1):e11-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Choristoma / diagnosis. Diagnosis, Differential. Female. Humans. Mixed Tumor, Mullerian / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390249.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. McWilliams RR, Bamlet WR, Rabe KG, Olson JE, de Andrade M, Petersen GM: Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol; 2006 Sep;4(9):1143-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma.
  • BACKGROUND & AIMS: Pancreatic adenocarcinoma has been associated with several familial cancer syndromes that also predispose to other malignancies.
  • The ages at diagnosis of those probands who reported a family history (first- or second-degree relative) of PC, breast, ovarian, colorectal cancer, or melanoma were compared with those probands who did not.
  • Multivariable regression analyses were performed with age at diagnosis as the primary outcome variable.
  • After controlling for tobacco exposure and gender, those probands with a family history of breast (-3.23 years, P = .001), ovarian (-5.63 years, P = .005), colorectal (-3.19 years, P = .002) cancers, and melanoma (-5.75 years, P = .017) had a younger age of onset of PC than those who did not.
  • CONCLUSION: A family history of cancers (breast, ovarian, colorectal, melanoma) associated with specific cancer syndromes that are known to contribute also to PC risk is associated with a younger onset of PC.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):199-205 [10698482.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):704-10 [16614112.001]
  • [Cites] Med Clin North Am. 2000 May;84(3):707-18 [10872427.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):84-96 [11815963.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Feb;16(1):1-16 [12063821.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):525-30 [12478670.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):180-1 [12569133.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):448-57 [12644538.001]
  • [Cites] Cancer Detect Prev. 2003;27(2):87-93 [12670518.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1292-9 [12730869.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):173-82 [14692038.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):516-9 [10404064.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1834-41 [15550590.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2722-6 [15534880.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):388-94 [15912495.001]
  • (PMID = 16861052.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA092049; United States / NCI NIH HHS / CA / K07 CA116303; United States / PHS HHS / / R25T 92049; United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / R01 CA097075
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS21380; NLM/ PMC1899874
  •  go-up   go-down


41. Mirer E, El Sayed F, Ammoury A, Lamant L, Messer L, Bazex J: Treatment of mammary and extramammary Paget's skin disease with topical imiquimod. J Dermatolog Treat; 2006;17(3):167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It can be confined to the epithelium or may be associated with an underlying adenocarcinoma.
  • The diagnosis is confirmed by skin biopsy and the treatment depends on characteristics of the underlying cancer.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Paget Disease, Extramammary / drug therapy. Paget's Disease, Mammary / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Groin. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Dermatolog Treat. 2007;18(3):191-2 [17538811.001]
  • (PMID = 16854759.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


42. Mohareb RM, Mohamed AA: The reaction of cyanoacetylhydrazine with omega-bromo(4-methyl)acetophenone: synthesis of heterocyclic derivatives with antitumor activity. Molecules; 2010 May;15(5):3602-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antitumor evaluation of the newly synthesized products against three cancer cell lines, namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) were recorded.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PYRIDINE .
  • Hazardous Substances Data Bank. ACETOPHENONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657502.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Acetophenones; 0 / Antineoplastic Agents; 0 / Heterocyclic Compounds; 0 / Hydrazines; 0 / Pyridines; 0 / Triazines; NH9L3PP67S / pyridine; RK493WHV10 / acetophenone; SK0DPC9098 / acetylhydrazine
  •  go-up   go-down


43. Kim TY, Kim WB, Gong G, Hong SJ, Shong YK: Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. Clin Endocrinol (Oxf); 2005 Feb;62(2):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The breast (five patients) was the most common primary site followed by the kidney (three), colon (three) and lung (three).
  • In the remaining 14 patients, the interval from diagnosis of primary tumour to the detection of thyroid metastasis varied from 8 months to 15 years, with a median of 54 months.
  • Breast cancer is the most common tumour that metastasizes to the thyroid.
  • They usually occur when there are metastases elsewhere, sometimes many years after the diagnosis of the original primary tumour and show poor prognosis in general.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma / diagnosis. Carcinoma / secondary. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Colonic Neoplasms / therapy. Esophageal Neoplasms / therapy. Female. Humans. Kidney Neoplasms / therapy. Lung Neoplasms / therapy. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670202.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


44. Ventham NT, Hussien MI: Male breast cancer is rare: an initial presentation may be as an abscess. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer is rare: an initial presentation may be as an abscess.
  • Breast cancer in men is rare.
  • Breast cancer presenting initially as an abscess has been described only a handful of times in the literature.
  • We present the first described case of invasive adenocarcinoma presenting as an abscess in a man.
  • An 80-year-old diabetic man presented with symptoms typical of a breast abscess.
  • The abscess failed to respond to percutaneous therapy and excision of breast abscess was performed.
  • Histology should be obtained from breast abscesses not resolving within 2 months of initial percutaneous therapy.
  • [MeSH-major] Abscess / pathology. Adenocarcinoma / pathology. Breast / pathology. Breast Neoplasms, Male / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Aged, 80 and over. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mastectomy / methods. Neoplasm Invasiveness / pathology. Risk Assessment. Tamoxifen / therapeutic use. Treatment Outcome. Ultrasonography, Doppler


45. Perepelytsina OM, Harmanchuk LV, Shevchenko IeA, Sydorenko MV, Ostapchenko LI: [Comparison of NO production level and proliferation of MCF-7 breast tumor cells under conditions of microenvironment modification]. Ukr Biokhim Zh (1999); 2010 Jul-Aug;82(4):60-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of NO production level and proliferation of MCF-7 breast tumor cells under conditions of microenvironment modification].
  • Connection between the level of NO generation and its cytotoxic influence was investigated on two models of tumor cells (breast adenocarcinoma MCF-7) culture: monolayer and spheroids.
  • [MeSH-major] Breast Neoplasms. Cell Proliferation. Nitric Oxide / biosynthesis. Spheroids, Cellular

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21516718.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] ukr
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Calcium Channels, L-Type; 0 / Culture Media; 31C4KY9ESH / Nitric Oxide; SY7Q814VUP / Calcium
  •  go-up   go-down


46. John AS, Hu X, Rothman VL, Tuszynski GP: Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion. Exp Mol Pathol; 2009 Dec;87(3):184-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We now report that TSP-1 up-regulates TIMP-1 expression in both human breast and prostate cancer cell lines.
  • The effect of TSP-1 on TIMP-1 expression was examined in human breast adenocarcinoma cell lines (MDA-MB-231) and human prostate cancer cell lines (PC3-NI and PC3-ML) treated with exogenous TSP-1.
  • TIMP-1 expression was also examined in TSP-1 stably transfected breast cancer cell line (MDA-MB-435).

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 2004 Jul;120(1):21-6 [15172186.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5292-3 [19549886.001]
  • [Cites] J Biol Chem. 1985 Oct 5;260(22):12240-5 [3930491.001]
  • [Cites] Blood. 1986 May;67(5):1197-209 [3516249.001]
  • [Cites] Exp Cell Res. 1986 Dec;167(2):376-90 [3770094.001]
  • [Cites] Cancer Res. 1987 Aug 1;47(15):4130-3 [3607754.001]
  • [Cites] J Cell Biol. 1987 Nov;105(5):2409-15 [3680388.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624-8 [1697685.001]
  • [Cites] Mol Biol Cell. 1992 Feb;3(2):181-8 [1550960.001]
  • [Cites] J Cell Biol. 1993 Jan;120(2):513-21 [8421063.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:541-73 [8280471.001]
  • [Cites] Int J Cancer. 1994 Oct 15;59(2):191-5 [7927918.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6788-92 [7624320.001]
  • [Cites] Proc Soc Exp Biol Med. 1996 Jul;212(3):199-207 [8677265.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):160-6 [9052425.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):436-41 [9139881.001]
  • [Cites] Exp Cell Res. 1997 Sep 15;235(2):403-12 [9299165.001]
  • [Cites] J Biol Chem. 1998 Feb 6;273(6):3604-10 [9452488.001]
  • [Cites] Exp Cell Res. 2006 Aug 1;312(13):2443-53 [16762342.001]
  • [Cites] Cancer Lett. 2007 Jun 18;251(1):28-35 [17188426.001]
  • [Cites] Circ Res. 2007 May 11;100(9):1308-16 [17413041.001]
  • [Cites] J Biol Chem. 1978 Dec 10;253(23):8609-16 [101549.001]
  • (PMID = 19747478.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA088931-01; United States / NCI NIH HHS / CA / R01 CA088931; United States / NCI NIH HHS / CA / R01 CA088931-01; United States / NCI NIH HHS / CA / R01 CA88931
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Thrombospondin 1; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS150758; NLM/ PMC2783349
  •  go-up   go-down


47. Ghule PN, Dominski Z, Lian JB, Stein JL, van Wijnen AJ, Stein GS: The subnuclear organization of histone gene regulatory proteins and 3' end processing factors of normal somatic and embryonic stem cells is compromised in selected human cancer cell types. J Cell Physiol; 2009 Jul;220(1):129-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More importantly, the in situ co-localization of p220(NPAT) and Lsm10 is disrupted in HeLa S3 cervical carcinoma cells and MCF7 breast adenocarcinoma cells, with most Lsm10 residing in Cajal Bodies.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10334-42 [17974976.001]
  • [Cites] J Cell Biochem. 2008 Aug 15;104(6):2016-26 [18615590.001]
  • [Cites] Cell Cycle. 2008 Aug;7(15):2357-67 [18677100.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):16964-9 [18957539.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2283-97 [10995386.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2298-313 [10995387.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:273-300 [11031238.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5470-9 [11574479.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1424-37 [11839809.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):17-21 [12379800.001]
  • [Cites] Mol Cell Biol. 2003 May;23(10):3669-80 [12724424.001]
  • [Cites] Genes Dev. 2003 Sep 15;17(18):2321-33 [12975319.001]
  • [Cites] Mol Cell. 2003 Aug;12(2):295-305 [14536070.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8110-23 [14585971.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8586-600 [14612403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Apr;71(4):1286-90 [4524638.001]
  • [Cites] Nucleic Acids Res. 1983 Apr 25;11(8):2391-410 [6304651.001]
  • [Cites] Mol Cell Biol. 1983 Nov;3(11):1920-9 [6656760.001]
  • [Cites] Biochemistry. 1987 Sep 22;26(19):6178-87 [3689769.001]
  • [Cites] Science. 1989 Nov 3;246(4930):603-8 [2683075.001]
  • [Cites] J Exp Med. 1991 Jun 1;173(6):1407-19 [2033369.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5915-9 [7597053.001]
  • [Cites] Cell Biol Int. 1996 Jan;20(1):41-9 [8936406.001]
  • [Cites] Genes Dev. 1996 Dec 1;10(23):3028-40 [8957003.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):456-61 [9472014.001]
  • [Cites] Gene. 2004 Nov 10;342(1):35-40 [15527963.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(14):6140-53 [15988025.001]
  • [Cites] J Biol Chem. 2005 Nov 11;280(45):37400-7 [16131487.001]
  • [Cites] J Cell Biol. 2006 Mar 13;172(6):875-84 [16533947.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):883-93 [16972248.001]
  • [Cites] J Cell Physiol. 2007 Feb;210(2):517-26 [17096384.001]
  • [Cites] Biochemistry. 2006 Dec 26;45(51):15915-20 [17176114.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):454-63 [17522714.001]
  • [Cites] Gene. 2007 Jul 15;396(2):373-90 [17531405.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2491-502 [17442888.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):9-17 [17520687.001]
  • (PMID = 19277982.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R37 DE012528; United States / NIGMS NIH HHS / GM / R01 GM058921-02; United States / NCI NIH HHS / CA / P01 CA082834-10; United States / NIGMS NIH HHS / GM / GM058921-02; United States / NCI NIH HHS / CA / CA082834-10; United States / NIGMS NIH HHS / GM / R01 GM032010-23; United States / NIGMS NIH HHS / GM / R01 GM058921; United States / NIGMS NIH HHS / GM / GM032010-23; United States / NCI NIH HHS / CA / P01 CA082834; United States / NIGMS NIH HHS / GM / R01 GM032010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Histones; 0 / LSM10 protein, human; 0 / NPAT protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Ribonucleoproteins, Small Nuclear
  • [Other-IDs] NLM/ NIHMS301281; NLM/ PMC3167205
  •  go-up   go-down


48. Kovács O, Kotsis L, Krasznai G: [Solitary oesophageal metastasis of breast cancer after 17 years latency]. Magy Seb; 2007 Dec;60(6):307-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary oesophageal metastasis of breast cancer after 17 years latency].
  • The authors discuss a case of a 63-year-old woman, who presented with dysphagia, 17 years after radical mastectomy for breast cancer.
  • A biopsy via right thoracotomy revealed a metastatic adenocarcinoma of the oesophageal wall from the previous breast carcinoma.
  • A combination of high clinical suspicion with EUS and deep oesophageal biopsy can lead to the correct diagnosis of this very rare clinical entity.
  • The biology of metastatic breast cancer may demand palliation by oesophageal intubation or stenting combined with adjuvant chemo, radio or hormonal therapy in such instances.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Breast Neoplasms / pathology. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / secondary. Esophagus. Intubation. Palliative Care / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065370.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


49. Panchuk R, Korynevska A, Stoika R: Effect of landomycin E on expression of mRNA coding for transforming growth factor beta ligands and specific receptors in MCF-7 cells. Exp Oncol; 2005 Dec;27(4):330-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to investigate regulation of mRNA, coding for TGFbeta ligands and specific receptors, by novel antitumor antibiotic landomycin E (LE) in human breast adenocarcinoma cells of MCF-7 line, sensitive and resistant to anti-cancer agent doxorubicin.
  • [MeSH-major] Adenocarcinoma / metabolism. Aminoglycosides / pharmacology. Antineoplastic Agents / pharmacology. Breast Neoplasms / metabolism. Gene Expression / drug effects. Transforming Growth Factor beta / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404356.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antineoplastic Agents; 0 / Ligands; 0 / RNA, Messenger; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 0 / landomycin E; 80168379AG / Doxorubicin
  •  go-up   go-down


50. Akers W, Lesage F, Holten D, Achilefu S: In vivo resolution of multiexponential decays of multiple near-infrared molecular probes by fluorescence lifetime-gated whole-body time-resolved diffuse optical imaging. Mol Imaging; 2007 Jul-Aug;6(4):237-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bacteriochlorophyll a (BC) and cypate-glysine-arginine-aspartic acid-serine-proline-lysine-OH (Cyp-GRD) were administered separately or combined to mice with subcutaneous xenografts of human breast adenocarcinoma and slow-release estradiol pellets for improved tumor growth.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711779.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109754; United States / NIBIB NIH HHS / EB / R01 EB1430; United States / NCI NIH HHS / CA / R24 CA83060; United States / NCI NIH HHS / CA / R33 CA100972
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacteriochlorophylls; 0 / Molecular Probes; 0 / Peptides
  •  go-up   go-down


51. Koval J, Mikes J, Jendzelovský R, Kello M, Solár P, Fedorocko P: Degradation of HER2 receptor through hypericin-mediated photodynamic therapy. Photochem Photobiol; 2010 Jan-Feb;86(1):200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current treatment of breast cancer is often affected by resistance to therapeutics, for which the human epidermal growth factor receptor 2 (HER2) may be responsible.
  • Here, we report for the first time the use of hypericin-mediated photodynamic therapy (HY-PDT) in combination with a selective HER2 inhibitor (AG 825) on SKBR-3, a HER2 overexpressing human breast adenocarcinoma cell line.
  • This knowledge provides the basis for the possible application of HY-PDT in preclinical and clinical models of breast cancer treatment.
  • [MeSH-major] Breast Neoplasms / therapy. Photochemotherapy / methods. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. PERYLENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19912559.001).
  • [ISSN] 1751-1097
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzothiazoles; 0 / Tyrphostins; 0 / tyrphostin AG825; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


52. Ypma PF, Wijermans PW, Koppen H, Sillevis Smitt PA: Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma. Neth J Med; 2006 Jul-Aug;64(7):243-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma.
  • PCD can accompany different kinds of neoplasms including small cell lung cancer, adenocarcinoma of the breast and ovary, and Hodgkin's lymphoma.
  • Despite extensive laboratory and radiological evaluations in this patient with rapidly deteriorating cerebellar syndrome, the diagnosis of a paraneoplastic syndrome was only made after several months, when an anti-Tr antibody was detected in his serum.
  • [MeSH-major] Cerebellum / pathology. Hodgkin Disease / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis


53. Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer; 2005 Oct 31;93(9):1046-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of different histologic types of breast cancer.
  • Breast cancer is a heterogeneous disease, though little is known about some of its rarer forms, including certain histologic types.
  • Using Surveillance, Epidemiology, and End Results Program data on 135 157 invasive breast cancer cases diagnosed from 1992 to 2001, relationships between nine histologic types of breast cancer and various tumour characteristics were assessed.
  • Among women aged 50-89 years at diagnosis, lobular and ductal/lobular carcinoma cases were more likely to be diagnosed with stage III/IV, > or =5.0 cm, and node-positive tumours compared to ductal carcinoma cases.
  • The histologic types of breast cancer studied here differ greatly in their clinical presentations, and the differences in their hormone receptor profiles and grades point to their likely different aetiologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1993 Jul;218(1):13-21 [8328824.001]
  • [Cites] JAMA. 2003 Mar 19;289(11):1421-4 [12636465.001]
  • [Cites] Arch Surg. 1979 Apr;114(4):485-8 [435063.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2254-9 [12805323.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2570-7 [10861435.001]
  • [Cites] JAMA. 2003 Jun 25;289(24):3254-63 [12824206.001]
  • [Cites] Natl Cancer Inst Monogr. 1981 Jun;(57):1-1082 [7278951.001]
  • [Cites] Breast Cancer Res Treat. 2004 May;85(1):23-9 [15039595.001]
  • [Cites] Int J Epidemiol. 1992 Apr;21(2):222-8 [1428473.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1128-35 [15247123.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1175-81 [14652277.001]
  • [Cites] Breast. 2000 Oct;9(5):267-70; discussion 270 [14732176.001]
  • [Cites] JAMA. 2002 Feb 13;287(6):734-41 [11851540.001]
  • [Cites] Histopathology. 1982 Mar;6(2):149-61 [7076138.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):1-7 [8478135.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):549-59; discussion 559-61 [7574934.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):342-51 [14746851.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2149-53 [14557212.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600 [12101105.001]
  • [Cites] Cancer Causes Control. 2003 Apr;14(3):225-33 [12814201.001]
  • [Cites] Breast Cancer Res. 2004;6(3):R149-56 [15084238.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1673-7 [8156495.001]
  • (PMID = 16175185.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA132383; United States / NCI NIH HHS / CA / U56 CA096286; United States / NCI NIH HHS / CA / U56 CA096288
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2361680
  •  go-up   go-down


54. Ra SH, Fishbein MC, Baruch-Oren T, Shintaku P, Apple SK, Cameron RB, Lai CK: Mucinous adenocarcinomas of the thymus: report of 2 cases and review of the literature. Am J Surg Pathol; 2007 Sep;31(9):1330-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The first case in a 61-year-old woman resembled a mucinous (colloid) carcinoma of other organs such as the breast and colon.
  • The second case in an 82-year-old woman was a mucinous adenocarcinoma arising from a thymic cyst with areas of transition from benign to dysplastic epithelium.
  • CONCLUSIONS: Mucinous adenocarcinoma, with or without, psammoma bodies, may be of primary thymic origin and should be considered in the differential diagnosis of malignant mediastinal tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Mediastinal Neoplasms / diagnosis. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antigens, CD5 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-5. Keratin-6 / analysis. Keratin-7 / analysis. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721187.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / KRT5 protein, human; 0 / KRT7 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Keratin-7
  • [Number-of-references] 18
  •  go-up   go-down


55. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E: Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett; 2007 Dec 18;258(2):181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
  • Metastatic breast cancer is an incurable disease, often characterized by poor response to standard chemotherapy, which is mainly based on anthracyclines and taxanes.
  • The present study investigates the effects of signal transducer and activator of transcription 3 (Stat3) inhibition on the response of the highly metastatic MDA-MB-231 human breast adenocarcinoma cell line to doxorubicin (DOX).
  • Stat3 is a transcription factor often constitutively activated in breast tumors and cancer cell lines, and is thought to contribute to malignant transformation and progression by transactivation of a host of target genes involved in cell proliferation and survival, angiogenesis and invasiveness.
  • (b) inhibiting the Stat3 signaling pathway, by exposure to the tyrphostin AG490 (an inhibitor of the upstream activating Janus kinases), by transfection with a dominant-negative form of Stat3 or by treatment with satraplatin (a tetravalent platinum derivative that inhibits Stat3 activation), increases breast cancer cell response to the proapoptotic effect of DOX (to different extents).
  • Overall, these observations suggest that suppression of Stat3 signaling may provide a potential therapeutic approach to overcoming DOX resistance in metastatic breast cancer cells.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line, Tumor. Cell Survival / drug effects. Female. Flow Cytometry. Humans. Immunoblotting. Neoplasm Metastasis. Organoplatinum Compounds / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / metabolism. Transfection

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920763.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / STAT3 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; 80168379AG / Doxorubicin; 8D7B37T28G / satraplatin; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


56. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, Wilczynski SP, Li J, You M, Pfeifer GP: Tumor susceptibility of Rassf1a knockout mice. Cancer Res; 2005 Jan 1;65(1):92-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors in Rassf1a-targeted mice included lung adenomas, lymphomas, and one breast adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / genetics. Animals. Base Sequence. Crosses, Genetic. DNA Primers. Genotype. Lung Neoplasms / genetics. Lymphoma / genetics. Mammary Neoplasms, Animal / genetics. Mice. Mice, Inbred C57BL. Mice, Knockout. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665283.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA093643; United States / NCI NIH HHS / CA / CA88873
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RASSF1 protein, mouse; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


57. Wu JJ, Cheng KW, Zuo XF, Wang MF, Li P, Zhang LY, Wang H, Ye WC: Steroidal saponins and ecdysterone from Asparagus filicinus and their cytotoxic activities. Steroids; 2010 Oct;75(10):734-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 1-10 were investigated for their cytotoxicities against human breast adenocarcinoma MDA-MB-231 cell line and compounds 8-10 exhibited cytotoxic activities with IC(50) values ranging from 3.4 to 6.6microM.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20470812.001).
  • [ISSN] 1878-5867
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Saponins; 0 / filiasparoside C; 5289-74-7 / Ecdysterone
  •  go-up   go-down


58. Luzhna L, Kovalchuk O: Modulation of DNA methylation levels sensitizes doxorubicin-resistant breast adenocarcinoma cells to radiation-induced apoptosis. Biochem Biophys Res Commun; 2010 Feb 5;392(2):113-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of DNA methylation levels sensitizes doxorubicin-resistant breast adenocarcinoma cells to radiation-induced apoptosis.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / radiotherapy. Breast Neoplasms / genetics. Breast Neoplasms / radiotherapy. DNA Methylation / drug effects. Radiation Tolerance / drug effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20034463.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 7LP2MPO46S / S-Adenosylmethionine; 80168379AG / Doxorubicin
  •  go-up   go-down


59. Cammarata PR, Flynn J, Gottipati S, Chu S, Dimitrijevich S, Younes M, Skliris G, Murphy LC: Differential expression and comparative subcellular localization of estrogen receptor beta isoforms in virally transformed and normal cultured human lens epithelial cells. Exp Eye Res; 2005 Aug;81(2):165-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we determined whether virally transformed cell cultures of human lens epithelial cells (HLE-B3) express both full length (or wt) and variant isoforms of ERbeta in comparison to normal secondary cultures of human lens epithelial cells (nHLE) and furthermore, identify the subcellular localization of the wtERbeta-1 and ERbeta isoform variants in HLE-B3 and nHLE cells, as well as from human breast adenocarcinoma cells (MCF-7) which provided a positive control.
  • Total RNA was extracted from HLE-B3 and nHLE cells and lens tissue, as well as from human breast adenocarcinoma cells (MCF-7) and subjected to RT-PCR using specific estrogen receptor primers intended to distinguish ERbeta-1-ERbeta-5 mRNA.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080910.001).
  • [ISSN] 0014-4835
  • [Journal-full-title] Experimental eye research
  • [ISO-abbreviation] Exp. Eye Res.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY05570
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor beta; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


60. McMahon K, Medoro L, Kennedy D: Breast magnetic resonance imaging: an essential role in malignant axillary lymphadenopathy of unknown origin. Australas Radiol; 2005 Oct;49(5):382-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast magnetic resonance imaging: an essential role in malignant axillary lymphadenopathy of unknown origin.
  • The aim of this retrospective case series was to assess the role of breast MRI in the investigation of "occult" malignancy, and the associated potential to influence patient management.
  • Between January 2000 and March 2004, 18 patients, who presented with axillary lymphadenopathy, most likely due to "occult" breast cancer, were examined with MRI of the breast.
  • As such, MRI of the breast is highly sensitive for the detection of mammographically and clinically occult breast cancer.
  • The use of MRI enables a preoperative diagnosis to be made in a high percentage of patients and may allow retrospective targeted ultrasound localization.
  • Definitive surgical planning, including the option of breast conservation, is made possible with the result of the MRI examination.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphatic Diseases / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Axilla. Contrast Media. Humans. Image Processing, Computer-Assisted. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174176.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


61. Sahoo S, Recant WM: Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast. Breast J; 2005 Mar-Apr;11(2):140-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast.
  • Columnar cell alteration in the breast encompasses a spectrum of pathologic changes ranging from simple columnar cell change to more complex columnar cell hyperplasia with and without atypia to in situ carcinoma, often with a micropapillary architecture.
  • Therefore it is important to be familiar with the spectrum of changes and the associated lesions, especially in breast core biopsies for further management.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Breast / pathology. Calcinosis / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730461.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Gong RX, Zhou Y, Luo SH, Zhang L, Zhou B: [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun;26(3):310-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no significant relationship between BRAF mutation and gender, age at the time of diagnosis, tumor size and distant metastasis.
  • [MeSH-major] Lymphatic Metastasis / genetics. Prognosis. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / genetics. Adult. Aged. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504446.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


63. Lehman CD, DeMartini W, Anderson BO, Edge SB: Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw; 2009 Feb;7(2):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for breast MRI in the patient with newly diagnosed breast cancer.
  • Use of breast MRI in the preoperative evaluation of patients recently diagnosed with breast cancer has increased significantly over the past 10 years because of its well-documented high sensitivity for detecting otherwise occult breast cancer in the affected and contralateral breasts.
  • Equally important are growing concerns that the quality of breast MRI may vary significantly across practice sites, and therefore the published value of MRI may not be achieved for many patients.
  • This article describes the peer-reviewed, published clinical research trials evaluating breast MRI in patients with newly diagnosed breast cancer on which the National Comprehensive Cancer Network (NCCN) practice guidelines are based.
  • The current NCCN guidelines recommend that breast MRI be considered for patients with a newly diagnosed breast cancer to evaluate the extent of ipsilateral disease and to screen the contralateral breast, particularly for women at increased risk for mammographically occult disease.
  • In addition, the guidelines indicate that breast MRI may be used for patients with axillary nodal adenocarcinoma to identify the primary malignancy.
  • The guidelines stress the importance of having proper equipment, imaging technique, and provider training necessary to achieve high-quality breast MRI, and emphasize that MRI practice sites should have the ability to perform MRI-guided biopsy or needle localization.
  • In addition to describing the data regarding use of breast MRI in women with newly diagnosed cancer, this article provides recommendations for the performance of high-quality breast MRI and suggestions for future research.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adenocarcinoma / diagnosis. Axilla. Biopsy, Needle. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Female. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Unknown Primary / pathology. Practice Guidelines as Topic. Sensitivity and Specificity. Surgery, Computer-Assisted

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200417.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


64. Miyake Y, Hirokawa M, Norimatsu Y, Kanahara T, Monobe Y, Ohno S, Miyamoto T, Yakushiji H, Sakaguchi T, Aratake Y, Ohno E: Mucinous breast carcinoma with myoepithelial-like spindle cells. Diagn Cytopathol; 2009 Jun;37(6):393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous breast carcinoma with myoepithelial-like spindle cells.
  • Appearance of spindle cells has been believed as a benign index of breast cytology.
  • But, we have frequently observed the spindle cells in smears from mucinous carcinoma of the breast.
  • Nineteen cases of breast mucinous carcinoma were used for cytological examination.
  • We assert that the presence of spindle cells can be a characteristic feature of mucinous carcinoma of the breast.
  • It should facilitate precise diagnosis of breast cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology


65. Chen CH, Rowlands C, Sengupta SK, George RL, Parulekar W, Thain K, O'Malley F, Isotalo PA: Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ. Breast J; 2009 Jul-Aug;15(4):409-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a primary invasive adenocarcinoma of the nipple with extensive basaloid features that was also associated with squamous cell carcinoma (SCC) in situ and an aggressive behavior.
  • A 69-year-old woman without a history of breast neoplasia presented with right nipple pain.
  • The differential diagnosis included a primary basaloid adenocarcinoma of the nipple, basal cell carcinoma of the nipple, neuroendocrine carcinoma, melanoma, basaloid variant of adenoid cystic carcinoma and metastatic disease.
  • Immunohistochemical profile of this tumor supported a primary basaloid adenocarcinoma of the nipple.
  • Although the initial sentinel lymph node biopsy was negative, within a year of diagnosis, the patient developed ipsilateral axillary node and pulmonary metastases.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601946.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


66. Ngo NT, Nguyen VT, Vo HV, Vang O, Duus F, Ho TD, Pham HD, Nguyen LH: Cytotoxic Coumarins from the Bark of Mammea siamensis. Chem Pharm Bull (Tokyo); 2010 Nov;58(11):1487-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The four coumarins, surangins C and D and theraphins B and C, were tested for inhibition of cell proliferation in DLD-1 (colon cancer), MCF-7 (breast adenocarcinoma), HeLa (human cervical cancer) and NCI-H460 (human lung cancer) cell lines using the sulforhodamine B (SRB) assay.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048341.001).
  • [ISSN] 1347-5223
  • [Journal-full-title] Chemical & pharmaceutical bulletin
  • [ISO-abbreviation] Chem. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Coumarins
  •  go-up   go-down


67. Frenkel M, Mishra BM, Sen S, Yang P, Pawlus A, Vence L, Leblanc A, Cohen L, Banerji P, Banerji P: Cytotoxic effects of ultra-diluted remedies on breast cancer cells. Int J Oncol; 2010 Feb;36(2):395-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effects of ultra-diluted remedies on breast cancer cells.
  • We conducted an in vitro study to determine if products prescribed by a clinic in India have any effect on breast cancer cell lines.
  • We studied four ultra-diluted remedies (Carcinosin, Phytolacca, Conium and Thuja) against two human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231) and a cell line derived from immortalized normal human mammary epithelial cells (HMLE).
  • The remedies exerted preferential cytotoxic effects against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Homeopathy / methods. Phytotherapy / methods


68. Kwatra KS, Prabhakar BR, Jain S: Oestrogen and progesterone receptors in primary mucinous carcinoma of skin. Australas J Dermatol; 2005 Nov;46(4):246-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine-needle aspiration cytology and histopathological examination showed a picture of mucinous adenocarcinoma.
  • Clinical examination and systemic investigations failed to detect any primary lesion elsewhere and hence, a diagnosis of primary mucinous carcinoma of the skin was made.
  • This tumour shows histological resemblance to mucinous carcinoma of breast.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197424.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


69. Tampio M, Markkanen P, Puttonen KA, Hagelberg E, Heikkinen H, Huhtinen K, Loikkanen J, Hirvonen MR, Vähäkangas KH: Induction of PUMA-alpha and down-regulation of PUMA-beta expression is associated with benzo(a)pyrene-induced apoptosis in MCF-7 cells. Toxicol Lett; 2009 Aug 10;188(3):214-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benzo(a)pyrene (BP) forms benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE)-DNA adducts in human breast adenocarcinoma MCF-7 cells, leading to p53 protein induction and phosphorylation.

  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397966.001).
  • [ISSN] 1879-3169
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BBC3 protein, human; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / Reactive Oxygen Species; 3417WMA06D / Benzo(a)pyrene; 9007-43-6 / Cytochromes c
  •  go-up   go-down


70. Kommareddy S, Amiji M: Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J Pharm Sci; 2007 Feb;96(2):397-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice.
  • The objective of the present study was to modify thiolated gelatin nanoparticles with poly(ethylene glycol) (PEG) chains and examine their long circulating and tumor-targeting properties in vivo in an orthotopic a human breast adenocarcinoma xenograft model.
  • The in vivo long-circulating potential, biodistribution and passive tumor targeting of the controls, and PEG-modified thiolated gelatin nanoparticles were evaluated by injecting indium-111 (111In)-labeled nanoparticles into breast tumor (MDA-MB-435)-bearing nude mice.
  • [MeSH-major] Breast Neoplasms / metabolism. Gelatin / chemistry. Nanoparticles. Polyethylene Glycols / chemistry. Sulfhydryl Compounds / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • Hazardous Substances Data Bank. GELATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17075865.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB-002027; United States / NCI NIH HHS / CA / R01-CA095522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Sulfhydryl Compounds; 30IQX730WE / Polyethylene Glycols; 9000-70-8 / Gelatin
  •  go-up   go-down


71. Barz M, Luxenhofer R, Zentel R, Kabanov AV: The uptake of N-(2-hydroxypropyl)-methacrylamide based homo, random and block copolymers by human multi-drug resistant breast adenocarcinoma cells. Biomaterials; 2009 Oct;30(29):5682-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The uptake of N-(2-hydroxypropyl)-methacrylamide based homo, random and block copolymers by human multi-drug resistant breast adenocarcinoma cells.
  • The cellular uptake of these polymers was investigated in the human multi-drug resistant breast adenocarcinoma cell line MCF7/ADR.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):271-84 [10699287.001]
  • [Cites] J Cell Biol. 1982 May;93(2):269-77 [6178742.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):169-85 [11259839.001]
  • [Cites] PDA J Pharm Sci Technol. 2001 May-Jun;55(3):191-201 [11417110.001]
  • [Cites] J Control Release. 2002 Aug 21;82(2-3):189-212 [12175737.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):845-54 [12538842.001]
  • [Cites] Nat Rev Drug Discov. 2003 Mar;2(3):214-21 [12612647.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):347-60 [12750738.001]
  • [Cites] Clin Pharmacokinet. 2003;42(13):1089-105 [14531722.001]
  • [Cites] Angew Chem Int Ed Engl. 1972 Dec;11(12):1103-4 [4630476.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jun 27;44(26):4061-6 [15912547.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Feb 13;45(8):1198-215 [16444775.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):688-701 [16900224.001]
  • [Cites] Chem Rev. 2007 Jun;107(6):2270-99 [17530906.001]
  • [Cites] Nat Mater. 2008 Jul;7(7):588-95 [18500347.001]
  • [Cites] Nat Nanotechnol. 2008 Mar;3(3):145-50 [18654486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11613-8 [18697944.001]
  • [Cites] Bioconjug Chem. 2008 Oct;19(10):2023-9 [18729494.001]
  • [Cites] Biomacromolecules. 2008 Nov;9(11):3114-8 [18855476.001]
  • [Cites] Pharm Res. 2008 Dec;25(12):2845-52 [18592353.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(29):5309-12 [19294716.001]
  • [Cites] Biomacromolecules. 2009 Jul 13;10(7):1697-703 [19425549.001]
  • [Cites] Eur J Pharm Biopharm. 2000 Jul;50(1):61-81 [10840193.001]
  • (PMID = 19631373.001).
  • [ISSN] 1878-5905
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089225-09; United States / NCI NIH HHS / CA / R01 CA089225; United States / NCI NIH HHS / CA / 2R01 CA89225; United States / NCI NIH HHS / CA / R01 CA089225-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Drug Carriers; 0 / Polymers; 21442-01-3 / N-(2-hydroxypropyl)methacrylamide
  • [Other-IDs] NLM/ NIHMS290104; NLM/ PMC3089424
  •  go-up   go-down


72. Gordon GJ, Deters LA, Nitz MD, Lieberman BC, Yeap BY, Bueno R: Differential diagnosis of solitary lung nodules with gene expression ratios. J Thorac Cardiovasc Surg; 2006 Sep;132(3):621-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of solitary lung nodules with gene expression ratios.
  • OBJECTIVE: We have developed a new technique that uses the ratios of select gene expression levels to translate complex genomic data into simple clinically relevant tests for the diagnosis and prognosis of cancer.
  • METHODS: We used gene expression profiling data to train a ratio-based predictor model to discriminate among a set of samples (n = 145 total) composed of normal lung, small cell lung cancer, adenocarcinoma, squamous cell carcinoma, and pulmonary carcinoid (the training set).
  • CONCLUSION: The gene expression ratio diagnostic technique is likely to aid in the differential diagnosis of solitary lung nodules in patients with suspected cancer and may also prove useful in developing lung cancer screening strategies that incorporate analysis of fine-needle aspiration specimens.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7437-46 [11704875.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):153-9 [11443621.001]
  • [Cites] Oncologist. 2001;6(2):147-52 [11306726.001]
  • [Cites] J Thorac Imaging. 2001 Jan;16(1):65-8 [11149694.001]
  • [Cites] Surg Endosc. 2000 Dec;14(12):1142-5 [11148784.001]
  • [Cites] Diagn Cytopathol. 2000 Apr;22(4):261-2 [10787152.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):448-62 [8834320.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4406-14 [15958625.001]
  • [Cites] Ann Thorac Surg. 1996 Sep;62(3):824-8; discussion 828-9 [8784013.001]
  • [Cites] Ann Thorac Surg. 1986 Jun;41(6):592-6 [3718033.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Sep 1;170(5):516-9 [15331390.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Jul 15;170(2):167-74 [15087295.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R3 [12052255.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4963-7 [12208747.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):794-801 [11895911.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1531-40 [11745232.001]
  • [Cites] Radiology. 2001 Dec;221(3):592-6; discussion 597 [11719649.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):905-10 [14504202.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):598-605 [12697852.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Nov;29(11):1894-9 [12465387.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):903-6 [14713850.001]
  • (PMID = 16935118.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA105249-02; United States / NCI NIH HHS / CA / R21 CA100315-01A1; United States / NCI NIH HHS / CA / R01 CA120528-01; United States / NCI NIH HHS / CA / R21 CA098501-01A1; United States / NCI NIH HHS / CA / CA100315-01A1; United States / NCI NIH HHS / CA / L30 CA109938-02; United States / NCI NIH HHS / CA / CA120528-01; United States / NCI NIH HHS / CA / CA100315-02; United States / NCI NIH HHS / CA / R03 CA105249; United States / NCI NIH HHS / CA / CA098501; United States / NCI NIH HHS / CA / R33 CA100315; United States / NCI NIH HHS / CA / CA105249; United States / NCI NIH HHS / CA / R21 CA100315; United States / NCI NIH HHS / CA / CA105249-01; United States / NCI NIH HHS / CA / L30 CA109938-01; United States / NCI NIH HHS / CA / R01 CA120528; United States / NCI NIH HHS / CA / CA109938-01; United States / NCI NIH HHS / CA / CA109938-02; United States / NCI NIH HHS / CA / R21 CA098501-02; United States / NCI NIH HHS / CA / CA098501-02; United States / NCI NIH HHS / CA / CA098501-01A1; United States / NCI NIH HHS / CA / R33 CA100315-02; United States / NCI NIH HHS / CA / R21 CA098501; United States / NCI NIH HHS / CA / R03 CA105249-01; United States / NCI NIH HHS / CA / CA105249-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS36822; NLM/ PMC2194803
  •  go-up   go-down


73. Tsao SC, Su YC, Wang SL, Chai CY: Use of caveolin-1, thyroid transcription factor-1, and cytokeratins 7 and 20 in discriminating between primary and secondary pulmonary adenocarcinoma from breast or colonic origin. Kaohsiung J Med Sci; 2007 Jul;23(7):325-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of caveolin-1, thyroid transcription factor-1, and cytokeratins 7 and 20 in discriminating between primary and secondary pulmonary adenocarcinoma from breast or colonic origin.
  • The objectives of this study were firstly to compare the immunostaining patterns of antibodies against caveolin-1, thyroid transcription factor-1 (TTF-1), cytokeratin 7 (CK7) and cytokeratin 20 (CK20) in primary and secondary pulmonary adenocarcinomas of breast or colonic origin, and secondly, to investigate their use alone and in combination, in distinguishing between primary and secondary lung adenocarcinomas from breast or colonic origin.
  • Of the 49 lung adenocarcinoma specimens that were enrolled in this study, 30 were primary pulmonary adenocarcinomas, and 19 (9, breast origin; 10, colonic origin) were metastatic pulmonary carcinomas.
  • Primary pulmonary adenocarcinoma most often had the CK7-positive/CK20-negative immunohistochemical phenotype and was either TTF-1 positive or caveolin-1 negative.
  • Secondary pulmonary adenocarcinoma of breast origin most often had the CK7-positive/CK20-negative immunohistochemical phenotype and was either TTF-1 negative or caveolin-1 positive, while secondary pulmonary adenocarcinoma of colonic origin most often had the CK20-positive/CK7-negative immunohistochemical phenotype and was either TTF-1 negative or caveolin-1 positive.
  • The results suggest that caveolin-1, TTF-1, or CK7/CK20 alone did not distinguish reliably between primary and secondary pulmonary adenocarcinomas originating from breast or colon.
  • The use of a panel of antibodies that includes TTF-1, caveolin-1, and CK7/CK20 may have higher sensitivity in discriminating between primary adenocarcinomas and metastatic lung adenocarcinomas from breast or colonic origin.
  • [MeSH-major] Adenocarcinoma / chemistry. Breast Neoplasms / pathology. Caveolin 1 / analysis. Colonic Neoplasms / pathology. DNA-Binding Proteins / analysis. Keratin-20 / analysis. Keratin-7 / analysis. Lung Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606426.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / DNA-Binding Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / TTF1 protein, human
  •  go-up   go-down


74. Moon H, Ahn H, Kodell RL, Baek S, Lin CJ, Chen JJ: Ensemble methods for classification of patients for personalized medicine with high-dimensional data. Artif Intell Med; 2007 Nov;41(3):197-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Personalized medicine is defined by the use of genomic signatures of patients in a target population for assignment of more effective therapies as well as better diagnosis and earlier interventions that might prevent or delay disease.
  • RESULTS: The proposed algorithm is applied to genomic data sets on lymphoma patients and lung cancer patients to distinguish disease subtypes for optimal treatment and to genomic data on breast cancer patients to identify patients most likely to benefit from adjuvant chemotherapy after surgery.
  • [MeSH-major] Algorithms. Diagnosis, Computer-Assisted. Gene Expression Regulation, Neoplastic. Neoplasms / diagnosis. Neoplasms / therapy. Patient Selection
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / therapy. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Breast Neoplasms / therapy. Chemotherapy, Adjuvant. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Lung Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Mesothelioma / diagnosis. Mesothelioma / genetics. Mesothelioma / therapy. Models, Statistical. Pleural Neoplasms / diagnosis. Pleural Neoplasms / genetics. Pleural Neoplasms / therapy. Reproducibility of Results. Software. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17719213.001).
  • [ISSN] 0933-3657
  • [Journal-full-title] Artificial intelligence in medicine
  • [ISO-abbreviation] Artif Intell Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


75. Ozeki J, Enomoto K, Sakurai K, Amano S: [A case of the breast cancer metastases to skin treated with local radiotherapy was effective]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2763-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of the breast cancer metastases to skin treated with local radiotherapy was effective].
  • Biopsy revealed a possibility of breast cancer metastases.
  • Mammography and the breast echography did not show any anomalies.
  • The diagnosis was latent breast metastasis.
  • In a breast cancer treatment, radiotherapy will be performed for the purpose of local control.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224705.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


76. Strik MW, Anders S, Barth M, Bärlehner E, Benecke C, Benhidjeb T: [Total videoendoscopic thyroid resection by the axillobilateral breast approach. Operative method and first results]. Chirurg; 2007 Dec;78(12):1139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total videoendoscopic thyroid resection by the axillobilateral breast approach. Operative method and first results].
  • [Transliterated title] Total-videoendoskopische Strumaresektion via "axillobilateral breast approach". Operative Technik und erste Ergebnisse.
  • BACKGROUND: The axillobilateral breast approach (ABBA) is a procedure allowing thyroid resection without scarring at the neck.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Cysts / surgery. Endoscopes. Minimally Invasive Surgical Procedures / instrumentation. Surgical Instruments. Thyroid Diseases / surgery. Thyroid Neoplasms / surgery. Thyroid Nodule / surgery. Thyroidectomy / instrumentation. Video-Assisted Surgery / instrumentation
  • [MeSH-minor] Adult. Axilla / innervation. Axilla / surgery. Biopsy, Needle. Female. Humans. Intraoperative Complications / diagnosis. Intraoperative Complications / prevention & control. Middle Aged. Monitoring, Intraoperative / instrumentation. Recurrent Laryngeal Nerve Injuries. Reoperation. Thyroid Gland / pathology. Ultrasonic Therapy / instrumentation. Vocal Cord Paralysis / diagnosis. Vocal Cord Paralysis / prevention & control

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chirurg. 2001 Sep;72(9):1054-7 [11594276.001]
  • [Cites] J Endocrinol Invest. 1999 Dec;22(11):849-51 [10710272.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1075-8 [15490052.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Dec;12(6):426-9 [12496549.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Jun;13(3):196-201 [12819505.001]
  • [Cites] Surg Endosc. 1997 Aug;11(8):877 [9266657.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):20-5 [12598753.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):926-32 [15671771.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]
  • (PMID = 17805497.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


77. Dhillon R, Depree P, Metcalf C, Wylie E: Screen-detected mucinous breast carcinoma: potential for delayed diagnosis. Clin Radiol; 2006 May;61(5):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screen-detected mucinous breast carcinoma: potential for delayed diagnosis.
  • RESULTS: Of the pure mucinous carcinomas, the average age at diagnosis was 65 years (range 48-82 years), which was higher than that of other women with breast cancer (average age 60 years) screened at BreastScreen WA.
  • However, none of these cases had positive axillary lymph nodes at final diagnosis.
  • CONCLUSION: Although mammographically benign appearances of mucinous carcinoma caused a delay in diagnosis in 38% of the present cases, mucinous breast carcinomas have a favourable prognosis, as they are often low-grade tumours and rarely metastasize.
  • Delay in diagnosis for these tumours in a screening programme may not lead to a significant adverse outcome for most women.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Breast Neoplasms / radiography
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / ultrasonography. Databases, Factual. Female. Humans. Mammography / methods. Middle Aged. Neoplasm Invasiveness. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679116.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Kilic-Okman T, Yardim T, Gücer F, Altaner S, Yuce MA: Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers Syndrome. Arch Gynecol Obstet; 2008 Jul;278(1):75-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers Syndrome.
  • Patients with PJS have increased risk for gastrointestinal, breast, and female genital tract cancers.
  • In 2003, concomitant to cervical carcinoma, breast cancer was diagnosed.
  • [MeSH-major] Breast Neoplasms / diagnosis. Gonadoblastoma / diagnosis. Ovarian Neoplasms / diagnosis. Peutz-Jeghers Syndrome / complications. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Biomarkers, Tumor / blood. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Fatal Outcome. Female. Humans. Mastectomy. Neoplasms, Multiple Primary


79. Uzan C, Andre F, Scott V, Laurent I, Azria E, Suciu V, Balleyguier C, Lacroix L, Delaloge S, Vielh P: Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer. Cancer; 2009 Feb 25;117(1):32-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer.
  • METHODS: Ultrasound- or palpation-guided FNAC was performed in 124 consecutive patients who had nodular breast lesions.
  • The most significant predictors of quality and quantity of mRNA were the cytopathologist who sampled the tumors and a diagnosis of cancer versus benign lesion.
  • CONCLUSIONS: In 70% of cases, FNAC of breast lesions in well trained hands allowed the extraction of mRNA suitable for gene expression analysis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Breast Neoplasms / diagnosis. RNA, Messenger / isolation & purification

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19347827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


80. Sharma S, Kotru M, Yadav A, Chugh M, Chawla A, Makhija M: Role of fine-needle aspiration cytology in evaluation of cutaneous metastases. Diagn Cytopathol; 2009 Dec;37(12):876-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung carcinoma was seen to metastasize most commonly to skin in males and breast carcinoma in females.
  • They were most commonly diagnosed as poorly differentiated carcinoma followed by adenocarcinoma.
  • FNAC can diagnose a variety of tumors in the skin and support the diagnosis of a metastasis in case of a known primary and offer a clue to underlying malignancy in case of an occult primary.
  • [MeSH-major] Biopsy, Fine-Needle. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530099.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Ishikawa T, Hamaguchi Y, Tanabe M, Momiyama N, Chishima T, Nakatani Y, Nozawa A, Sasaki T, Kitamura H, Shimada H: False-positive and false-negative cases of fine-needle aspiration cytology for palpable breast lesions. Breast Cancer; 2007;14(4):388-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive and false-negative cases of fine-needle aspiration cytology for palpable breast lesions.
  • BACKGROUND: Fine-needle aspiration cytology (FNA) is less traumatic and technically easy to apply to small breast tumors.
  • METHODS: A total of 382 cases of palpable breast lesions that had undergone fine needle aspiration and histopathologic diagnosis were reviewed with an emphasis on the rate of false positive diagnoses in benign breast lesions.
  • RESULTS: A diagnosis of " malignant " was made in 98 of the 382 specimens (25.6%).
  • CONCLUSION: Palpable breast tumors can be definitively diagnosed based on a combination of physical examination, radiological studies and FNA, when the radiological studies concur with the diagnosis by FNA.
  • [MeSH-major] Biopsy, Needle. Breast Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adult. Cytodiagnosis. False Negative Reactions. False Positive Reactions. Female. Humans. Neoplasm Invasiveness. Neoplasms, Ductal, Lobular, and Medullary / parasitology. Predictive Value of Tests. Prognosis. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986804.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Conscience I, Perceau G, Le Berruyer PY, Bernard P: [Bilateral breast bacterial cellulite secondary to Streptococcus agalactiae septicemia]. Ann Dermatol Venereol; 2006 Feb;133(2):171-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral breast bacterial cellulite secondary to Streptococcus agalactiae septicemia].
  • BACKGROUND: We report a case of group B streptococcal septicemia of digestive origin with secondary bilateral breast dermal-hypodermal localization.
  • CASE REPORT: A 71 year-old woman with a past history of bilateral breast cancer treated by conservation therapy was hospitalized because of the sudden occurrence of two clearly delimited, inflammatory, dermal-hypodermal cutaneous plaques located on each breast, associated with fever (39 degrees C), 4 days after a colonoscopy.
  • Histological examination of a sigmoid polyp revealed a tubular adenocarcinoma.
  • [MeSH-major] Breast Diseases / etiology. Cellulitis / etiology. Sepsis / complications. Streptococcal Infections / complications. Streptococcus agalactiae
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / surgery. Aged. Amoxicillin / administration & dosage. Amoxicillin / therapeutic use. Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Anti-Infective Agents / administration & dosage. Anti-Infective Agents / therapeutic use. Clavulanic Acid / administration & dosage. Clavulanic Acid / therapeutic use. Colonic Polyps / diagnosis. Colonic Polyps / surgery. Colonoscopy. Drug Therapy, Combination. Female. Humans. Metronidazole / administration & dosage. Metronidazole / therapeutic use. Rifampin / administration & dosage. Rifampin / therapeutic use. Sigmoid Neoplasms / complications. Sigmoid Neoplasms / diagnosis. Sigmoid Neoplasms / surgery. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - Cellulitis.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16508605.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 140QMO216E / Metronidazole; 23521W1S24 / Clavulanic Acid; 804826J2HU / Amoxicillin; VJT6J7R4TR / Rifampin
  •  go-up   go-down


83. Fiszman GL, Middonno MC, de la Torre E, Farina M, Español AJ, Sales ME: Activation of muscarinic cholinergic receptors induces MCF-7 cells proliferation and angiogenesis by stimulating nitric oxide synthase activity. Cancer Biol Ther; 2007 Jul;6(7):1106-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We here evidence that similarly to previous results obtained in mice, human breast tumor homogenates over expressed mAChR in comparison with normal breast tissue.
  • Thus, to test the muscarinic actions on human breast adenocarcinoma cells we investigate the effect of CARB on MCF-7 cells proliferation and neovascular response.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Neovascularization, Pathologic / etiology. Nitric Oxide Synthase / physiology. Receptors, Muscarinic / physiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611397.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Muscarinic; 0 / Vascular Endothelial Growth Factor A; 8Y164V895Y / Carbachol; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


84. Lozano MV, Torrecilla D, Torres D, Vidal A, Domínguez F, Alonso MJ: Highly efficient system to deliver taxanes into tumor cells: docetaxel-loaded chitosan oligomer colloidal carriers. Biomacromolecules; 2008 Aug;9(8):2186-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluorescence was observed in more than 80% of MCF7 (human breast adenocarcinoma) and almost 100% of A549 (human lung carcinoma) cells when a 2 h treatment with fluorescent CS carriers was given.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637687.001).
  • [ISSN] 1526-4602
  • [Journal-full-title] Biomacromolecules
  • [ISO-abbreviation] Biomacromolecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Colloids; 0 / Fluorescent Dyes; 0 / Nanocapsules; 0 / Taxoids; 15H5577CQD / docetaxel; 9012-76-4 / Chitosan
  •  go-up   go-down


85. Zhang HG, Qi C, Wang ZH, Jin G, Xiu RJ: Evaluation of a new CA15-3 protein assay method: optical protein-chip system for clinical application. Clin Chem; 2005 Jun;51(6):1038-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adult. Aged. Biosensing Techniques. Breast Neoplasms / diagnosis. Carcinoma, Lobular / diagnosis. Carcinoma, Medullary / diagnosis. Female. Humans. Middle Aged. Optics and Photonics. Protein Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817821.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-1
  •  go-up   go-down


86. Gok B, McGirt M, Sciubba DM, Ayhan S, Bydon A, Witham TF, Wolinsky JP, Gokaslan ZL: Surgical resection plus adjuvant radiotherapy is superior to surgery or radiotherapy alone in the prevention of neurological decline in a rat metastatic spinal tumor model. Neurosurgery; 2008 Aug;63(2):346-51; discussion 351
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty-two Fischer 344 rats underwent a transabdominal approach for implantation of a CRL-1666 breast adenocarcinoma cell line within the vertebral body of L6.

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797365.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Qureshi HS, Linden MD, Divine G, Raju UB: E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters. Am J Clin Pathol; 2006 Mar;125(3):377-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters.
  • We stained 276 breast carcinomas with monoclonal antibodies to EC (invasive lobular carcinomas [ILC] and variants, 59; invasive ductal carcinoma and ductal special types [IDC], 204; tubulolobular carcinoma [TLC], 4; and invasive carcinoma [IC], uncertain whether lobular or ductal type, 9).
  • Statistically a correlation of EC loss with a positive diagnosis of ILC was found but there was no correlation with any prognostic tumor variables.
  • A negative EC stain confirms the diagnosis of ILC (specificity, 97.7%; negative predictive value, 96.8%; sensitivity, 88.1%; positive predictive value, 91.2%).
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cadherins / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / classification. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Cell Count. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613340.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


88. Gomes N, Legrand C, Fauvel-Lafève F: Shear stress induced release of von Willebrand factor and thrombospondin-1 in HUVEC extracellular matrix enhances breast tumour cell adhesion. Clin Exp Metastasis; 2005;22(3):215-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shear stress induced release of von Willebrand factor and thrombospondin-1 in HUVEC extracellular matrix enhances breast tumour cell adhesion.
  • We have submitted endothelial cells (HUVEC) to shear stress (13 dynes/cm(2)) and isolated their extracellular matrix (ECM) prior perfusion with breast adenocarcinoma cells (MDA-MB-231) in whole blood at a shear rate of 1500 s(-1).
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Endothelial Cells / physiology. Extracellular Matrix / physiology. Thrombospondin 1 / physiology. von Willebrand Factor / physiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 1995 Oct;73(4):565-76 [7474929.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2725-34 [10515876.001]
  • [Cites] Thromb Haemost. 1986 Jun 30;55(3):415-35 [3750272.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):553-61 [15679053.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):11949-56 [11812775.001]
  • [Cites] Cell. 1987 Feb 27;48(4):549-54 [3028640.001]
  • [Cites] J Med Chem. 2000 Jan 13;43(1):22-6 [10633035.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3971-7 [12010796.001]
  • [Cites] Biorheology. 2003;40(1-3):41-5 [12454385.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Jun;29(6):861-5 [9304800.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11 Suppl):S61-5 [9413404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1968 Sep;61(1):46-52 [5246932.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2022-7 [2478219.001]
  • [Cites] Hum Pathol. 1992 Oct;23(10):1159-66 [1383121.001]
  • [Cites] APMIS. 2001 Apr;109(4):241-62 [11469496.001]
  • [Cites] N Engl J Med. 1990 Mar 1;322(9):605-12 [2406604.001]
  • [Cites] Eur J Biochem. 1985 Dec 16;153(3):435-43 [3935437.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1976 Sep 24;87(1):1-15 [136107.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):530-6 [9484807.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1558-64 [9269774.001]
  • [Cites] Thromb Res. 1995 Aug 1;79(3):261-74 [8533122.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5892-900 [8621462.001]
  • [Cites] C R Acad Sci III. 1996 Apr;319(4):333-41 [8762981.001]
  • [Cites] Thromb Haemost. 2001 Mar;85(3):552-9 [11307830.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1789-97 [10961878.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):471-7 [8375932.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):173-89 [8548867.001]
  • [Cites] J Exp Med. 1998 Feb 2;187(3):329-39 [9449713.001]
  • [Cites] Thromb Haemost. 2001 Nov;86(5):1148-55 [11816699.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1490-2 [12824298.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1082-92 [11676859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4591-5 [8506304.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):1867-74 [10471033.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1853-8 [11172040.001]
  • [Cites] J Med Chem. 1997 Jul 18;40(15):2289-92 [9240343.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6757-64 [2208139.001]
  • [Cites] J Thromb Haemost. 2003 Jul;1(7):1335-42 [12871266.001]
  • [Cites] Clin Exp Metastasis. 1992 Mar;10(2):125-37 [1371433.001]
  • [Cites] Histochem Cell Biol. 2002 Feb;117(2):113-22 [11935287.001]
  • [Cites] Blood. 1993 Dec 15;82(12 ):3622-30 [7505120.001]
  • [Cites] Am J Physiol. 1988 Jun;254(6 Pt 2):H1059-64 [3381893.001]
  • [Cites] J Med Chem. 1992 Nov 13;35(23):4393-407 [1447740.001]
  • [Cites] Thromb Haemost. 1995 Jul;74(1):282-90 [8578473.001]
  • [Cites] Curr Opin Lipidol. 2000 Apr;11(2):167-77 [10787179.001]
  • [Cites] Int J Cancer. 1997 Jan 17;70(2):201-7 [9009161.001]
  • [Cites] Clin Hemorheol Microcirc. 2000;23(1):1-11 [11214708.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4478-85 [11296290.001]
  • [Cites] Am J Physiol. 1992 Feb;262(2 Pt 1):C384-90 [1539628.001]
  • [Cites] Adv Cancer Res. 1990;54:159-211 [1688681.001]
  • [Cites] Invasion Metastasis. 1983;3(2):81-97 [6677623.001]
  • [Cites] Biochem Biophys Res Commun. 2000 May 19;271(3):584-8 [10814505.001]
  • [Cites] Thromb Res. 1993 Aug 1;71(3):193-204 [8211887.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):1927-34 [10471041.001]
  • [Cites] J Lab Clin Med. 1983 Oct;102(4):522-35 [6619647.001]
  • [Cites] Int J Biochem Cell Biol. 1997 May;29(5):721-5 [9251239.001]
  • [Cites] Thromb Haemost. 1989 Jun 30;61(3):485-9 [2508257.001]
  • [Cites] Mol Med Today. 1999 Jan;5(1):40-6 [10088131.001]
  • [Cites] J Cell Biochem. 1996 Sep 15;62(4):431-42 [8891889.001]
  • (PMID = 16158249.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Platelet Glycoprotein GPIIb-IIIa Complex; 0 / Platelet Glycoprotein GPIb-IX Complex; 0 / Thrombospondin 1; 0 / von Willebrand Factor
  •  go-up   go-down


89. Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS, Tregubova NA, Pryzimirska TV, Montgomery B, Rusetskaya NV, Pogribny IP: Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett; 2006 Jan 8;231(1):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
  • In the present study, we used human MCF-7 breast adenocarcinoma cell line and its doxorubicin-resistant variant MCF-7/R to determine the role of alterations of DNA methylation of chemoresitance-related genes, such as multidrug resistance 1 (MDR1), glutathione-S-transferase (GSTpi), O(6)-methylguanine DNA methyltransferase (MGMT), and urokinase (Upa), in the development of drug resistance.
  • [MeSH-major] Adenocarcinoma / pathology. Antibiotics, Antineoplastic / pharmacology. Breast Neoplasms / pathology. DNA Methylation. Doxorubicin / pharmacology. Drug Resistance, Neoplasm / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356834.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / Glutathione Transferase; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


90. Ietimalar H, Koksal A, Chelik N, Kasap B, Chukurova K, Iuldarum A: [Evaluation of mammography and risk of developing breast cancer in patients with ovarian or endometrial cancer]. Akush Ginekol (Sofiia); 2009;48(5):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of mammography and risk of developing breast cancer in patients with ovarian or endometrial cancer].
  • AIM: In this study our aim is to evaluate the reproductive factors determining the risk for breast cancer and the mammographical density in patients with ovarian or endometrial carcinoma.
  • MATERIALS AND METHODS: 24 patients with epithelial ovarian carcinoma and 35 patients with endometrial adenocarcinoma who were hospitalized at Izmir Ataturk Training and Research Hospital between the dates of May 2005 and June 2006 for diagnosis, treatment and follow-up were included to our study.
  • All patients were questioned by means of reproductive risk factors for breast cancer.
  • DISCUSSION: Reproductive risk factors for breast cancer in patients with ovarian and endometrial carcinoma were not different from the healthy population.
  • The results of our study didn't reflect the reported increased risk rates for breast cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Mammography. Ovarian Neoplasms / diagnosis


91. Vaccaro CA, Bonadeo F, Roverano AV, Peltomaki P, Bala S, Renkonen E, Redal MA, Mocetti E, Mullen E, Ojea-Quintana G, Benati ML, Rivello HG, Clark MB, Lynch JF, Lynch HT: Hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in Argentina: report from a referral hospital register. Dis Colon Rectum; 2007 Oct;50(10):1604-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 306 affected members, 197 cases of colorectal cancer were identified (mean age at diagnosis, 52.1 (range, 21-90) years).
  • The most frequent extracolonic tumors were gastric adenocarcinoma in males and endometrium adenocarcinoma in females.
  • A high incidence of breast cancer was observed (16 cases among 155 females, crude rate: 11,594.20/100,000).
  • A novel C deletion at 1910 nucleotide, codon 637, exon 12 of MSH2 gene was identified in a family with a strong aggregation of breast cancer with lack of MSH2 immunohistochemical staining.
  • The elevated incidence of breast cancer and its association with a novel hMSH2 mutation bring to consideration the inclusion of this malignancy as part of the syndrome.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Lynch syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846840.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


92. Zhang K, Li N, Chen Z, Shao K, Zhou F, Zhang C, Mu X, Wan J, Li B, Feng X, Shi S, Xiong M, Cao K, Wang X, Huang C, He J: High expression of nuclear factor of activated T cells in Chinese primary non-small cell lung cancer tissues. Int J Biol Markers; 2007 Jul-Sep;22(3):221-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Nuclear factor of activated T cells (NFAT) has been reported to be involved in the development of various types of cancer including adenocarcinoma of the breast.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922467.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 094964; United States / NCI NIH HHS / CA / CA 103180; United States / NCI NIH HHS / CA / CA 112557; United States / NIEHS NIH HHS / ES / ES 012451
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NFATC Transcription Factors
  •  go-up   go-down


93. Zhou XF, Zhang L, Tseng E, Scott-Ramsay E, Schentag JJ, Coburn RA, Morris ME: New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors. Drug Metab Dispos; 2005 Mar;33(3):321-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efflux of cytotoxic agents mediated by P-glycoprotein is believed to be an important mechanism of multidrug resistance, which remains a serious limitation to successful chemotherapy in cancers such as metastatic breast cancer.
  • [(3)H]Vinblastine accumulation studies indicated that at a concentration level of 3 muM, 15 of 18 4-aryl-1,4-dihydropyridines and all 4-arylpyridines can successfully restore intracellular accumulation of vinblastine in a resistant human breast adenocarcinoma cell line, MCF-7/adr, which overexpresses P-glycoprotein.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585608.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Calcium Channels; 0 / Dihydropyridines; 0 / P-Glycoprotein; 0 / Pyridines; 5V9KLZ54CY / Vinblastine; Z81N45O25Z / niguldipine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


94. Insabato L, Simonetti S, De Cecio R, Di Tuoro S, Bifulco G, Di Spiezio Sardo A: Primary signet-ring cell carcinoma of the uterine cervix with long term follow-up: case report. Eur J Gynaecol Oncol; 2007;28(5):411-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The uterine cervix represents an exceptional localization of signet-ring cell adenocarcinoma (SRCA).
  • Most commonly, endocervical tumors with such morphology are metastatic from the breast or gastrointestinal tract while primary pure or almost pure tumors are extremely rare.
  • CASE REPORT: The present report describes such a case of a 46-year-old woman without evidence of recurrence eight years after the diagnosis.
  • The histological diagnosis showed neoplastic signet-ring cells confined in the head of the cervical polyps with minimal stromal infiltration.
  • The present case represents an exceptional long-term survival, probably related to an early diagnosis and a prominent polypoid growth of the neoplasia outside the uterus.


95. Nguyen-Huu BK, Urban PP, Schreckenberger M, Dieterich M, Werhahn KJ: Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer. Mov Disord; 2006 Aug;21(8):1285-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The paraneoplastic amphiphysin(+) stiff-person syndrome (SPS) has so far only been described in women with breast adenocarcinoma.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Stiff person syndrome.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Movement Disorder Society
  • (PMID = 16671079.001).
  • [ISSN] 0885-3185
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Nerve Tissue Proteins; 147954-52-7 / amphiphysin
  •  go-up   go-down


96. Nott SL, Huang Y, Kalkanoglu A, Harper K, Chen M, Paoni SF, Fenton BM, Muyan M: Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer. Mol Med; 2010 Jan-Feb;16(1-2):10-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.
  • The main circulating estrogen hormone 17beta-estradiol (E2) contributes to the initiation and progression of breast cancer.
  • Ablation of the circulating E2 and/or prevention of ER functions constitute approaches for ER-positive breast cancer treatments.
  • These modalities are, however, ineffective in de novo endocrine-resistant breast neoplasms that do not express ERs.
  • We herein tested the prediction that specific regulation of ERE-driven genes by an engineered monomeric and constitutively active transcription factor, monotransregulator, provides a basis for the treatment of ER-negative breast cancer.
  • Using adenovirus infected ER-negative MDA-MB-231 cells derived from a breast adenocarcinoma, we found that the monotransregulator, but not the ERE-binding defective counterpart, repressed cellular proliferation and motility, and induced apoptosis through expression of genes that required ERE interactions.
  • Similarly, the monotransregulator suppressed the growth of ER-negative BT-549 cells derived from a breast-ductal carcinoma.
  • Thus, specific regulation of genes bearing EREs could offer a therapeutic approach for de novo endocrine-resistant breast cancers.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Exp Med Biol. 2008;630:206-19 [18637493.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Jan;41(1):155-63 [18805503.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1749-59 [19188451.001]
  • [Cites] J Biol Chem. 2009 May 29;284(22):15277-88 [19321454.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):400-14 [19440234.001]
  • [Cites] Mol Cell Biol. 2009 Sep;29(18):4949-58 [19620290.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):501-13 [10682656.001]
  • [Cites] Eur J Cancer. 2000 Sep;36 Suppl 4:S34-5 [11056309.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):311-7 [11162939.001]
  • [Cites] Vitam Horm. 2001;62:231-52 [11345900.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):71-84 [11384865.001]
  • [Cites] Mol Cell Endocrinol. 2001 Sep;182(2):249-63 [11514059.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):36869-72 [11459850.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Inflamm Res. 2003 Jan;52(1):39-49 [12608648.001]
  • [Cites] Mol Endocrinol. 2003 Apr;17(4):589-99 [12554772.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2046-51 [12727818.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4562-74 [12959972.001]
  • [Cites] Breast Cancer Res Treat. 2003;80 Suppl 1:S29-34; discussion S35 [14535532.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7316-39 [14576841.001]
  • [Cites] Nat Med. 2004 Jan;10(1):40-7 [14702633.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 15;218(1-2):65-78 [15130512.001]
  • [Cites] Cell. 1987 Dec 24;51(6):941-51 [3690665.001]
  • [Cites] Nature. 1988 Oct 6;335(6190):563-4 [3047590.001]
  • [Cites] Cell. 1988 Oct 7;55(1):145-56 [3167974.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11538-42 [1454845.001]
  • [Cites] Mol Cell Biol. 1993 Mar;13(3):1666-74 [8441404.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3675-85 [8098843.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):5004-11 [8402691.001]
  • [Cites] Cell. 1993 Nov 5;75(3):567-78 [8221895.001]
  • [Cites] Methods Mol Biol. 1998;91:217-38 [9664496.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14636-44 [15722343.001]
  • [Cites] Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):379-96 [16375692.001]
  • [Cites] Mol Cell. 2006 Sep 15;23(6):809-18 [16973433.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] FASEB J. 2006 Dec;20(14):2432-4 [17142791.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):487-99 [17157789.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S45-51 [17259558.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):4021-34 [17095510.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11530-9 [17307735.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):230-43 [17893877.001]
  • [Cites] J Mol Endocrinol. 2008 May;40(5):211-29 [18434428.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):12819-30 [18337247.001]
  • [Cites] Biochem Soc Trans. 2008 Aug;36(Pt 4):603-8 [18631125.001]
  • (PMID = 19946606.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113682; United States / NCI NIH HHS / CA / CA113682
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 4TI98Z838E / Estradiol
  •  go-up   go-down


97. Spiliopoulos D, Spiliopoulos M, Dandolu V, Mastrogiannis D: Vulvar and breast Paget's disease with synchronous underlying cancer: a unique association. Arch Gynecol Obstet; 2009 Aug;280(2):313-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulvar and breast Paget's disease with synchronous underlying cancer: a unique association.
  • BACKGROUND: We report a unique case of Paget's disease of vulva and breast.
  • Sequentially the patient had invasive ductal carcinoma of the breast, 5 years later was diagnosed with vulvar Paget's with underlying adenocarcinoma and after another 2 years was diagnosed with Paget's disease of the breast.
  • CASE: A 58-year-old woman with invasive ductal cancer of the left breast was treated with lumpectomy, lymph node dissection, radiation therapy and tamoxifen.
  • Five years later and after complaints of longstanding vulvar pruritus, the patient was diagnosed with vulvar Paget's disease and treated with simple vulvectomy, which revealed a concurrent underlying adenocarcinoma.
  • Seven years after the initial diagnosis of the breast cancer, a biopsy of a left areolar red, ulcerated lesion revealed Paget's disease of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local. Neoplasms, Second Primary. Paget Disease, Extramammary / pathology. Paget's Disease, Mammary / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Ductal, Breast / therapy. Female. Humans. Middle Aged


98. Schiel R, Müller UA, Braun A, Stein G, Kath R: Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur J Med Res; 2005 Aug 17;10(8):339-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no significant differences regarding incidence of total malignancies or carcinoma of the breast, the lung, renal cells or gonads.
  • Knowledge of these mechanisms should have important implications for the direction of strategies to prevent the development of malignancies, or to enhance ability to make an earlier diagnosis and more effective therapies.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Adult. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / etiology. Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / epidemiology. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131475.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Insulin
  •  go-up   go-down


99. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ: Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol; 2005 Jan;18(1):105-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.
  • Although immunohistochemistry has proven to be valuable in the differentiation of epithelioid mesothelioma from pulmonary or metastatic adenocarcinoma, no single antibody has demonstrated absolute sensitivity or specificity in making this distinction.
  • Using immunohistochemical analysis with D2-40, a recently available monoclonal antibody that has been used as a lymphatic endothelial marker, we examined 53 cases of mesothelioma, 28 cases of reactive pleura, 30 cases of pulmonary adenocarcinoma, 35 cases of renal cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and seven cases of urothelial carcinoma.
  • In addition, immunohistochemistry using calretinin, cytokeratin 5/6, and WT1 was performed on all cases of mesothelioma, pulmonary adenocarcinoma, ovarian serous carcinoma, and renal cell carcinoma.
  • We conclude that D2-40 immunoreactivity is sensitive for cells of mesothelial origin, and may be useful in the differential diagnosis of epithelioid malignant mesothelioma vs adenocarcinoma.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389250.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40; 0 / oncofetal antigens
  •  go-up   go-down


100. Rabinovich PM, Komarovskaya ME, Wrzesinski SH, Alderman JL, Budak-Alpdogan T, Karpikov A, Guo H, Flavell RA, Cheung NK, Weissman SM, Bahceci E: Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum Gene Ther; 2009 Jan;20(1):51-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reprogrammed CD3+ CD8+, CD3+ CD4+, and natural killer (NK ) cells toward autologous and allogeneic targets such as B cells, Daudi lymphoma, primary melanoma, breast ductal carcinoma, breast adenocarcinoma, and rhabdomyosarcoma.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2001 Feb 1;248(1-2):67-76 [11223069.001]
  • [Cites] Immunol Lett. 2008 Feb 15;116(1):7-14 [18164076.001]
  • [Cites] J Immunother. 2002 May-Jun;25(3):243-51 [12000866.001]
  • [Cites] Cancer Immunol Immunother. 2002 Oct;51(8):417-23 [12202902.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):255-6 [12529469.001]
  • [Cites] Nat Med. 2003 Mar;9(3):279-86 [12579196.001]
  • [Cites] Hybrid Hybridomics. 2003 Aug;22(4):209-18 [14511566.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1419-24 [14973056.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Cancer Gene Ther. 2004 May;11(5):371-9 [15060573.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4048-54 [11358824.001]
  • [Cites] J Surg Res. 1969 Mar;9(3):151-7 [5813183.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8200-4 [7545296.001]
  • [Cites] Science. 1997 Jun 13;276(5319):1719-24 [9180086.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1622-31 [15507526.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Nat Rev Immunol. 2005 Dec;5(12):928-40 [16322746.001]
  • [Cites] Curr Gene Ther. 2006 Feb;6(1):1-15 [16475942.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2294-302 [16282341.001]
  • [Cites] Cytotherapy. 2006;8(2):105-17 [16698684.001]
  • [Cites] Hum Gene Ther. 2006 Oct;17(10):1027-35 [17007566.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10995-1004 [17108138.001]
  • [Cites] Haematologica. 2007 Mar;92(3):381-8 [17339188.001]
  • [Cites] Annu Rev Immunol. 2007;25:243-65 [17129181.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1466-76 [17549249.001]
  • [Cites] Exp Hematol. 2007 Sep;35(9):1388-97 [17656004.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):524-31 [18083376.001]
  • (PMID = 19025415.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 1P01-HL-63357; United States / NCI NIH HHS / CA / 1P50 CA121974; United States / NCI NIH HHS / CA / CA-106450; United States / NHLBI NIH HHS / HV / N01-HV-28186
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Recombinant Fusion Proteins
  • [Other-IDs] NLM/ PMC2855249
  •  go-up   go-down






Advertisement